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Abstract
Association of individual and combined metabolic risk factors with cancer
Ruchi Bhandari, M.P.A., M.B.A.

Introduction: The prevalence of metabolic risk factors (MRFs), individually and in the
aggregate, is growing rapidly. There is limited biologic and epidemiologic evidence indicating an
association between MRFs and cancer. The goal of this dissertation was to examine the
association between individual and combined MRFs with subsequent risk of overall and sitespecific cancers of the breast, digestive system, and lung.
Methods: A systematic review with meta-analysis on the association between metabolic
syndrome (a cluster of MRFs) and breast cancer was conducted. In addition, associations
between MRFs and risk of overall and site-specific cancers were assessed by multivariable Cox
proportional hazards regression models. Lastly, associations between MRFs and age at cancer
onset were examined by multiple linear regression analyses, using the general linear model. Data
were derived from the NHANES I Epidemiologic Follow-up Study, and comprised participants
ages 25 to 74 years at baseline. The primary metabolic risk factors were obesity (measured by
BMI), high blood pressure, high total serum cholesterol, and diabetes. Analyses were adjusted
for age, race, education, family income, physical activity, smoking status, and family history of
cancer, and stratified by age and gender. All analyses incorporated the complex sample design
and sample weights to produce national estimates.
Results: Results from the meta-analysis show that metabolic syndrome was modestly associated
with an increased risk for breast cancer in adult women. Findings from the study on the
association between individual and combined MRFs and cancer risk suggest that diabetes
independently, and presence of a combination of MRFs, may serve as markers for
postmenopausal breast cancer risk. The association between diabetes and a combination of three
or four MRFs and earlier age at onset was observed not only for postmenopausal breast cancer,
but also for overall cancer in women 50 and older, digestive cancer in women, and lung cancer in
males.
Conclusion: Future research needs to examine this association between MRFs and site-specific
cancers using specific, objective metabolic markers. The positive association of MRFs with
postmenopausal breast cancer points toward the need to develop public health strategies to
manage these risk factors.
Keywords: Metabolic syndrome, metabolic risk factors, cancer, meta-analysis, breast cancer
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CHAPTER 1. INTRODUCTION
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1.1

Introduction
Cancer, the "plague of our generation,"1 will have been diagnosed in 1.7 million men and

women in the US in 2013.2 Accounting for one in four deaths, cancer is the second most
common cause of death in the United States (US) after heart disease.3 There are four important
causes of cancer: (a) genetic factors, (b) lifestyle factors, (c) infections, and (d) environmental
exposures.4 Only 5-10% of all cancers can be attributed to genetic causes.4 Lifestyle factors play
a significant role in cancer development and progression. The World Cancer Research Fund
estimates that 25-33% of new cancer cases in the US in 2013 are related to behavioral and
lifestyle factors, such as overweight or obesity, physical inactivity, and poor nutrition.5 Research
studies estimate half of the cancer burden can be prevented or significantly reduced by
modifying lifestyle factors.6, 7
Lifestyle factors can generate metabolic abnormalities that include overweight and
obesity, and high blood pressure, cholesterol, and blood glucose. Epidemiologic evidence
supports the association between each of these individual metabolic risk factors (MRFs) and
cancer risk.8-22 A few studies have also reported that cancer risk increases with the number of
MRFs.23-33
Several complex biological mechanisms have been proposed to show metabolic risk
factors promoting carcinogenesis. In brief, metabolic risk factors, functioning through various
mechanisms, including increased inflammatory markers, such as tumor necrosis factor-alpha and
interleuken-6, increased adipokines such as leptin, and decreased adiponectin, increased levels of
free fatty acids and triglycerides, insulin resistance, increased insulin-like growth factor-1, and
increased oxidative stress, can cause angiogenesis, cell migration, mitogenesis, and DNA
damage.34
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Despite the epidemiologic studies and limited experimental evidence supporting the
biological role of MRFs in cancer development and progression, results from studies examining
the association between individual and combined MRFs and overall cancer are inconsistent.
Therefore, the goal of this dissertation was to assess the individual and combined effects of
MRFs on subsequent risk of cancer. It comprises three inter-related studies on cancer risk from
metabolic risk factors. The background and methods of each of the three papers from the
dissertation are discussed briefly.
1.2

Study 1 Background: Metabolic Syndrome is associated with increased breast cancer

risk: A systematic review with meta-analysis
In the first paper of this dissertation, a systematic review with meta-analysis was
conducted to comprehensively synthesize existing literature on the association between
metabolic syndrome and breast cancer incidence. The most common cancer in women
worldwide is breast cancer, which accounted for 1.38 million new cases in 2008, comprising
approximately a quarter (23%) of all new cancer cases.35 Traditional risk factors for breast
cancer are well known as age, family history of cancer, and reproductive and menstrual history,
but lifestyle risk factors such as overweight, lack of physical activity, and consumption of
alcohol are also crucial.36 Several of these risk factors are associated with metabolic syndrome
(MS).37
Metabolic syndrome (MS) is a cluster of pathophysiological disorders comprising central
obesity, insulin resistance, high blood pressure, and dyslipidemia.37 MS has been identified as a
risk factor for several cancers, particularly breast, pancreatic, colorectal, and prostate cancers.25,
26, 28, 30-32, 38-45

Individual components of MS are positively associated with the development of

certain cancers, most notably breast cancer.46-52 Yet, studies show mixed results in these
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associations.29, 33, 53 Although some of the components of MS may not be strongly associated
with the development of breast cancer, they may all work together to elevate the risk.34 This
possibility suggests that MS may influence breast tumorigenesis by activating different
molecular pathways through endocrine, metabolic, and immune cell changes.54
However, results from previous epidemiologic studies are inconsistent with respect to MS
and breast cancer risk. Given the conflicting results from individual studies of MS and breast
cancer risk in all adult women, this study used the aggregate data meta-analytic approach to
examine the association between MS and BC risk in women. Studies were retrieved by searching
four electronic reference databases [PubMed, Cumulative Index to Nursing and Allied Health
Literature (CINAHL), Web of Science, and PROQUEST - June 30, 2012], and cross-referencing
from retrieved articles. Eligible for inclusion were longitudinal studies that reported associations
between MS and breast cancer risk among females aged 18 years and older. Relative risks (RR)
and associated 95% confidence intervals (95% CI) were calculated for each study, and then
pooled using fixed and random-effects models. Publication bias was assessed both quantitatively
(trim and fill)55 and qualitatively (funnel plots). Heterogeneity was examined using Q and I2
statistics.56
1.3

Study 2 Background: Association between individual and combined metabolic risk

factors and subsequent risk of cancer
Comprehensive reviews provide evidence of association between individual MRFs, such
as obesity, hypertension, diabetes, hypercholesterolemia, and overall and site-specific cancers.
Epidemiologic reviews provide evidence of individuals with diabetes at a higher risk for most
cancers.9, 10, 12, 16, 18, 49 Studies also show an association between obesity and several cancers.11, 13-
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15, 17, 47, 48, 57-59

However, results are less consistent for studies examining the association between

blood pressure, cholesterol, and cancer.19, 20, 60-66
There is adequate evidence that the risk for heart disease and stroke increases with
number of MRFs.67, 68 A combination of three or more of the MRFs is generally termed as
metabolic syndrome.37 Metabolic syndrome is estimated to be prevalent in over a third of US
adults.69 A recent meta-analysis found that the combination of MRFs (metabolic syndrome) also
elevated the risk for several cancers.24
Findings from observational as well as intervention studies have raised the hypothesis of
an etiologic link between the clustering of MRFs and elevated risk of cancer.70 Several complex
biological mechanisms have been proposed to show that MRFs promote carcinogenesis. The
prevalence of hyper-insulinemia and insulin resistance is higher in obese individuals. Hyperinsulinemia reduces the production of insulin-like growth factor (IGF) binding protein, resulting
in increased bioavailability of IGF-1.8 IGF-1 may promote tumor development by stimulating
cell proliferation and inhibiting apoptosis. Increased circulating insulin can also reduce the levels
of sex-hormone-binding-globulin, thereby increasing endogenous sex-steroid levels.8 Breast,
endometrial, and colorectal cancers may be affected by this mechanism.71 Another carcinogenic
mechanism involves cytokines. Increased adiposity raises cytokine production in obese women,
which in turn can induce estradiol production.34 Estradiol is a strong growth factor for breast and
endometrial cancers. Leptin, another adipocyte-specific hormone, is directly related to adiposity
and insulin resistance. It has direct stimulatory effects on cancer cells and may serve as an
important link between obesity and carcinogenesis.34
However, studies are not consistent in predicting an elevated cancer risk from MRFs.
With the background of increasing prevalence of metabolic syndrome, and epidemiologic
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evidence and biologic possibility of the association between MRFs and cancer risk, this study
examined the association of MRFs (obesity, high blood pressure, high total serum cholesterol,
and diabetes), individually and in combination, and subsequent risk of overall and site-specific
cancers of the breast, digestive system, and lung respectively.
Data were derived from the NHANES I Epidemiologic Follow-up Study, and comprised
participants ages 25 to 74 years at baseline. Multivariable Cox proportional hazards regression
models were fitted to assess the association between individual and combined MRFs and cancer
incidence. Analyses were adjusted for age, race, education, family income, physical activity,
smoking status, and family history of cancer, and stratified by age and gender. All analyses
incorporated the complex sample design and sample weights in order to generate national
estimates.
1.4

Study 3 Background: Association between metabolic risk factors and age at cancer

onset
Several epidemiologic studies have shown that MRFs elevate the risk of overall and
several site-specific cancers.8-22, 23-33 However, very few studies have examined whether MRFs
are associated with earlier age at cancer onset. There are a few studies showing overweight,
obesity, and hypertension being associated with earlier age at cancer onset.59, 66, 72
Animal studies suggest that mechanisms which prevent metabolic abnormalities, by
reducing serum IGF-1 or androgen concentrations, may delay the growth and progression of
breast and prostate cancers.73 An animal study found that mammary tumors developed earlier in
diet-induced obese rats than in lean rats, supporting the role of hormones and adipokines
(produced by adipose tissue) in cell proliferation and carcinogenesis.74
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The aim of this study was to examine whether MRFs, either individually or in
combination, were associated with age at onset of all-site cancer, and cancer of the breast,
digestive system, and lung respectively. It is an important research question for several reasons.
First, studies show that age at onset of certain cancers, such as breast, cervical, and prostate
cancers, is temporally decreasing.75 Second, earlier cancer onset shortens life expectancy,
signifying major loss of potential years of life.76-78 Third, compared with older patients, younger
cancer patients are likely to have more aggressive cancers, less favorable prognosis, and poorer
outcomes.76-78 Fourth, earlier age at cancer onset in a family may increase cancer risk for the next
generation.79, 80
Data were derived from the NHANES I Epidemiologic Follow-up Study, and
comprised participants ages 25 to 74 years at baseline. The outcome variable was age at cancer
onset, and the primary metabolic risk factors were obesity, high blood pressure, high total serum
cholesterol, and diabetes. Analyses were adjusted for age, race, education, family income,
physical activity, smoking status, and family history of cancer, and stratified by age and gender.
Multiple linear regression analyses, using the general linear model, were conducted to assess the
relationship between MRFs and age at cancer onset. All analyses incorporated the complex
sample design and sample weights to produce national estimates.
Each of the three papers is presented in detail in the next three chapters (Chapters 2-4).
The last chapter (Chapter 5) summarizes the findings from each of the papers and raises key
discussions points before concluding this research study.
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CHAPTER 2. METABOLIC SYNDROME IS ASSOCIATED WITH INCREASED
BREAST CANCER RISK: A SYSTEMATIC REVIEW WITH META-ANALYSIS

14

2.1

Abstract

Background
While positive and statistically significant associations between individual metabolic risk
factors and breast cancer risk have been reported, controversy surrounds risk of breast cancer
from metabolic syndrome (MS). We report the first systematic review and meta-analysis of the
association between MS and breast cancer risk in all adult females.
Methods
Studies were retrieved by searching four electronic reference databases [PubMed,
Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, and
PROQUEST - June 30, 2012], and cross-referencing from retrieved articles. Eligible for
inclusion were longitudinal studies that reported associations between MS and breast cancer risk
among females aged 18 years and older. Relative risks (RR) and associated 95% confidence
intervals (95% CI) were calculated for each study, and then pooled using random-effects models.
Publication bias was assessed both quantitatively (trim and fill) and qualitatively (funnel plots).
Heterogeneity was examined using Q and I2 statistics.
Results
Representing nine independent cohorts and 97,277 adult females, eight studies met the
inclusion criteria. A modest, positive association was observed between MS and breast cancer
risk (RR: 1.47, 95% CI, 1.15-1.87; z = 3.13; p = 0.002; Q = 26.28, p =.001; I2 = 69.55%). No
publication bias was observed.
Conclusions
MS is associated with an increased risk for breast cancer in adult women.
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2.2

Introduction
Breast cancer, the most common cancer in women worldwide, accounted for 1.38 million

new cases in 2008, comprising approximately a quarter (23%) of all new cancer cases.1 While
traditional risk factors for breast cancer include age, family history of cancer, and reproductive
and menstrual history, the National Cancer Institute also recognizes overweight, lack of physical
activity, and consumption of alcohol as risk factors.2 Several of these risk factors are associated
with metabolic syndrome.3
Metabolic syndrome (MS) is a cluster of pathophysiological disorders comprising central
obesity, insulin resistance, high blood pressure, and dyslipidemia. Reaven’s definition of MS in
19884 was followed by definitions from the World Health Organization,5 National Cholesterol
Education Program's Adult Treatment Panel III (NCEP ATP III),6 American Heart
Association/National Heart, Lung, and Blood Institute,7 and the International Diabetes
Federation.8 The NCEP’s ATP III guidelines are the most commonly used criteria in the U.S.6
These criteria include the presence of three or more of the following3: abdominal obesity (waist
circumference  35 inches in women), triglycerides  150 mg/dL, high density lipoprotein
cholesterol (HDL-C) < 50 mg/dL, blood pressure (BP)  130/85 mmHg, and fasting glucose 
110 mg/dL. MS is estimated to be prevalent in at least a quarter of the adults in the Americas, in
Europe, and in India.9
MS has been identified as a risk factor for several cancers, particularly breast, pancreatic,
colorectal, and prostate cancers.10-15 Individual components of MS, for example, abdominal
obesity, high blood glucose, high BP, high triglycerides, and low HDL, are positively associated
with the development of certain cancers, most notably breast cancer.16-27 While studies show a
positive association of breast cancer with diabetes19, 28-33 and obesity,16, 34, 35 others show a
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negative association with obesity in premenopausal women.36-38 Mixed results also characterize
hypertension22, 23,39, 40 and dyslipidemia22, 41, 42 as risk factors for breast cancer.
Although individual components of MS may not be strongly associated with the
development of breast cancer, their combination may elevate the risk.13, 14, 43-56 For example, MS
may activate different molecular pathways through endocrine, metabolic, and immune cell
changes, which in turn influence breast tumorigenesis.47 Such pathways that enhance breast
cancer cell proliferation and inhibit apoptosis, include: (1) increased levels of circulating
estrogen, e.g., estradiol,52, 54, 57 (2) higher levels of insulin,58, 59 (3) decreased level of circulating
adiponectin,60 and (4) increased plasma leptin concentration.60
Results from previous epidemiologic studies are inconsistent with respect to MS and
breast cancer risk. For example, only four13, 14, 43, 51 of eight studies13, 14, 43, 48, 51, 61-63 reported a
statistically significant association between MS and risk of breast cancer. Therefore, one might
conclude that the association between MS and breast cancer risk is unknown. However, such a
conclusion would be based on the vote-counting approach, an approach that ignores the
magnitude of the association.64
A recent systematic review and meta-analysis of MS and postmenopausal breast cancer
found that MS was moderately associated with the risk of postmenopausal breast cancer.10
However, to the best of our knowledge, no meta-analytic research has addressed the conflicting
results from individual studies of MS and breast cancer risk in all adult women. Therefore, the
purpose of this study was to use the aggregate data meta-analytic approach to examine the
association between MS and breast cancer risk in women.
2.3

Methods

2.3.1 Study Eligibility
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The a priori inclusion criteria for this study were as follows: (1) observational studies
using cohort (both prospective and retrospective), case-control, or nested case-control study
designs; (2) studies examining the association between MS (presence of a cluster of three or
more metabolic abnormalities) and breast cancer incidence, as defined by the authors; (3) studies
with adult females ≥ 18 years of age as participants; (4) English-language studies published as
journal articles, doctoral dissertations, or masters’ theses; (5) published and indexed studies up to
June 30, 2012; and (6) studies reporting sufficient data (e.g., rate ratios, risk ratios, odds ratios,
standardized incidence ratios, hazard ratios, or frequencies) for calculating a common effect size.
Studies not meeting all inclusion criteria were excluded from this review. Excluded
studies were those that: (1) were not published as full reports, such as conference abstracts and
letters to editors; (2) only examined individual components of MS; (3) measured the MS
variables at the time of cancer diagnosis; (4) used cancer mortality, rather than incidence, as the
outcome; and (5) studies published in a language other than English.
2.3.2 Data Sources
A comprehensive and systematic search was conducted using four electronic databases:
PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science,
and PROQUEST (from their commencement to June 30, 2012). Since the term MS dates back to
the late 1950s, with variations in use as early as the 1920s, the start dates of each of the databases
were used as the commencement date for study search; Web of Science (1900), CINAHL (1952),
PubMed (1966), and Proquest (1861). In addition, cross-referencing from retrieved studies was
also performed. Major keywords used in the search for potentially eligible studies included
“metabolic syndrome” (“insulin resistance syndrome,” “syndrome x,”) and “breast cancer”
(“neoplasm and breast”). Using the most recent publication, trials published as duplicate reports
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(parallel publications) were only included once. All electronic searches were conducted using the
graphical user interface for each database. The last search was conducted on June 30, 2012.
2.3.3 Study Selection
At the first screening, one author screened all abstracts and selected articles for full-text
examination. At the second level of the study selection process, two of the authors examined the
full-text articles and then selected the included studies following mutual discussion and
consensus.
2.3.4 Data Extraction
Two of the authors reviewed every study selected and independently extracted data from
studies onto electronic coding forms. These forms could hold up to 52 items per study. Attempts
were made to contact authors of three of the original studies for missing information,13, 61, 63 but
only one provided the requested information.13 After initial coding, the two coders reviewed each
item for agreement. Discrepancies were resolved by consensus. Using Cohen’s kappa (k)
statistic,65 the overall inter-rater agreement rate prior to correcting discrepant items, was 0.96 for
all included studies.
2.3.5 Risk of Bias Assessment
Risk of bias was assessed using a modified version of the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) checklist.66 The items assessed included: (1)
study design, (2) adjustments for confounders, (3) selection of participants and their eligibility
criteria, (4) measurement of predictor variables, (5) breast cancer diagnosis, (6) study size, (7)
handling of missing data, and (8) reasons for non-participation of individuals at each stage of the
study. A description of the criteria for risk of bias assessment is shown in Table 1. Two of the
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authors conducted all assessments, independent of each other. Disagreements were resolved
through discussion. No study was excluded based on the results of the risk of bias assessment.
2.3.6 Statistical Analysis
Calculation of study-level effect sizes. Risk estimates were used to examine the
association between MS and risk of breast cancer. These were derived from reported relative
risks, odds ratios, hazard ratios, incident rate ratios, or standardized incidence ratios, together
with their respective 95% CIs, from the original studies. Where necessary and possible, all
metrics were converted to risk ratios (RRs). Adjusted risk estimates from multivariable models
in the original studies were pooled for analysis. However, for two case-control studies that were
included,14, 51 adjusted odds ratios were used because data necessary to convert to RR were not
available.
Effect size pooling. All RR results were pooled using a random-effects model, an
approach that incorporates between-study heterogeneity into the model.67 A z-score two-tailed
alpha value ≤0.05 was considered as statistically significant. In addition, 95% confidence
intervals (CIs) were calculated for each result from each study as well as for pooled estimates.
Heterogeneity was calculated using the Q68 and I2 statistics.69 An alpha level ≤ 0.10 for the Q
statistic was considered as evidence of statistically significant heterogeneity. While somewhat
arbitrary, I2 values of 25%, 50%, and 75% were considered to represent low, moderate and high
amounts of heterogeneity.69 Publication bias was assessed using the Trim and Fill approach of
Duval and Tweedie.70 In addition, Rosenthal’s Fail-Safe N test was used to compute the number
of missing null studies that would be needed to nullify the overall pooled RR as being
statistically significant.71 Statistically significant standardized residuals (p < 0.05) were
considered as outliers.
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Sensitivity analyses. In order to examine the effects of each result from each study on the
overall pooled results, influence analysis was conducted with each result from each study deleted
from the model once. Cumulative meta-analysis, ranked by year, was also conducted in order to
examine the accumulation of results over time. A separate pooled analysis limited to
postmenopausal women was conducted because studies show that MS in postmenopausal women
increases the risk of breast cancer.13, 14, 43, 48, 51, 61 In addition, pooled analyses were conducted
with the following caveats post hoc: (1) deletion of results from two case-control studies because
odds ratios were used instead of RR,14, 51 (2) deletion of results from studies that were not
prospective cohort designs,13, 14, 51 and (3) limiting the results to studies that controlled for four
or more of the important confounders (as listed in Table 1).14, 43, 48, 51 All analyses were
performed using Comprehensive Meta-Analysis, Version 2.2.72
2.4

Results

2.4.1 Study Characteristics
Figure 1 presents a flow diagram of the selection of studies for the meta-analysis. Of the
291 studies screened, 47 (16.2%) were selected for full-text review: 25 from PubMed,14, 43-55, 63,
73-82

100

17 from the Web of Science,13, 39, 62, 83-96 one from CINAHL,97 and four from ProQuest.61, 98-

Of the 47 that underwent a full-text review, eight (17.0%) met the eligibility criteria.13, 14, 43,

48, 51, 61-63

One article14 presented results for two independent cohorts; therefore, each cohort was

treated independently.
A general description of the included studies is shown in Table 2. Studies were published
between 2008 and 2012 and from five different countries. The study designs included four
prospective cohorts,48, 61-63 one retrospective cohort,13 one prospective nested case-control,43 and
two case-control.14, 51 The baseline year for cohort inception ranged from 1983 to 2004, with
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average follow-up ranging between 2.7 and 13.5 years. Sample sizes ranged from 792 to 49,172
(total 97,277) adult females, excluding one study that did not report this data.63 The ages of the
participants ranged from 21 to 86 years. Six studies conducted analyses on postmenopausal
women.13, 14, 43, 48, 51, 61 The results of each cohort or case-control study were initially reported as
a hazard ratio,13, 48, 62 incidence rate ratio,43, 61 standardized incidence ratio,63 or odds ratio.14, 51
Methods for exposure assessment, cancer identification and the controlling of confounders varied
across the eight included studies (Table 3). Seven of the eight studies identified the outcome
(breast cancer) through histological reports, medical reports, or from a cancer registry,13, 14, 43, 48,
51, 61, 63

48, 63

while one used self-report.62 Only three studies examined invasive breast cancer cases.43,

One study also reported on the in situ breast cancer cases but there were only seven such

cases in that study.43 Another study analyzed all breast cancer cases (in situ and invasive) as well
as invasive cancers separately, and the results remained the same in both analyses.48
2.4.2 Risk of Bias Assessment
Risk of bias results are shown in Table 4. All the studies were considered to be at low
risk for selection of participants and meeting eligibility criteria as well as providing adequately
powered sample sizes. Out of eight studies, a majority were also considered low risk with respect
to study design (six studies) and measurement of the outcome variable (seven studies). In terms
of handling potential confounders, half the studies were low risk, three were high risk, and one
was unclear. Missing confounding variables included education, smoking status, alcohol use,
family history of cancer, contraceptive use, or hormonal history. Similarly, half the studies had
objective measurements of predictor variables, while the remainder relied on self-report, and
were consequently considered high risk. Four studies deleted the participants with missing
variables in their analyses (high risk), while two did not report how they handled missing data.
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Lastly, six studies were considered high risk because they did not report the reasons for nonparticipation of subjects at each stage of follow-up.
2.4.3 Statistical Analysis
Overall Results. Overall, a statistically significant increase of 47% in the risk for incident
breast cancer was observed for adult females with MS (RR: 1.47, 95% CI, 1.15-1.87; z = 3.13; p
< 0.002; Q = 26.28, p <0.001; I2 = 69.55%) (Figure 2). With the exception of one study,62 all
other studies had RR in the direction of increased risk.13, 14, 43, 48, 51, 61, 63 Funnel plot results for
potential publication bias are shown in Figure 3. Using the Trim and Fill approach that resulted
in two imputations, the risk decreased by 16% but remained significant (RR: 1.31, 95% CI, 1.011.70). The fail-safe N was 69, implying that 69 'null' studies would be needed to nullify the
statistically significant association between MS and breast cancer risk in adult females. No
statistically significant outliers were identified (p = 0.06-0.82).
Sensitivity analysis. With each study deleted from the model once, results remained
positive and statistically significant (Figure 4). As can be seen, the pooled RR fell within a range
of 20% (RR = 1.36-1.56) and none of the CIs for the point estimates was less than 1.0.
Cumulative meta-analysis, ranked by year, revealed that results have been statistically significant
since 2011 (Figure 5). Deleting the two case-control studies from the model, the RR for incident
breast cancer for women with MS decreased by 18% but was still statistically significant with
moderate heterogeneity (RR: 1.29, 95% CI, 1.003-1.67; z = 1.98; p = 0.05; Q = 14.13, p = .01; I2
= 64.61%). When limited to studies with only prospective designs, the RR decreased by 30% but
remained statistically significant with very low heterogeneity (RR: 1.17, 95% CI, 1.01-1.36; z =
2.04; p =0.04; Q = 4.30, p = 0.37; I2 = 7.04%). When limited to postmenopausal women, breast
cancer risk increased by 34% and was still statistically significant with high heterogeneity (RR:
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1.81, 95% CI, 1.28-2.56; z = 3.37; p =0.001; Q = 23.36, p =0.001; I2 = 74.32%). Lastly, when
limiting the results to studies that controlled for four or more of the important confounders (as
listed in Table 1),14, 43, 48, 51 breast cancer risk increased by 17% and was statistically significant
with moderate heterogeneity (RR: 1.64, 95% CI, 1.23-2.20; z = 3.34; p =0.001; Q = 8.55, p
=0.07; I2 = 53.21%).
2.5

Discussion
The purpose of this aggregate data meta-analysis was to examine the association between

MS and the risk for breast cancer in adult females. Overall results suggest that a modest positive
association exists between MS and risk of breast cancer. This finding is strengthened by the
robustness of results from other analyses. These include: (1) examination for publication bias, (2)
influence analysis with each study deleted from the model once, (3) deletion of the two casecontrol studies with odds ratios from the overall model, (4) limiting the analysis to prospective
designs, (5) including only postmenopausal women in the analysis, and (6) limiting the results to
studies that controlled for four or more of the important confounders. The results from
cumulative meta-analysis, ranked by year, indicate an increasingly statistically significant
association since 2011.
Assessment for risk of bias indicated that a majority of studies were at low risk regarding
study design, cancer assessment, and sample size. However, a majority were at high risk or
unclear risk in terms of handling of missing data and non-participation of subjects at each stage
of follow-up. It is suggested that future studies provide complete information on the handling of
missing data and on the non-participation of subjects at each stage of follow-up.
When limited to postmenopausal women, a stronger association between MS and breast
cancer was observed. This association was stronger in case-control and retrospective cohort
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study designs compared with prospective cohort study designs. These findings concur with the
recent meta-analysis on MS and breast cancer risk in postmenopausal women.10 Several studies
have shown that MS in postmenopausal women increases the risk of breast cancer,43, 46, 101
suggesting that the etiology of breast cancer may differ among pre and postmenopausal women.
There are several potential mechanisms linking MS with the increased risk of breast
cancer. First, obese postmenopausal women produce higher levels of estrogens, which in turn
increase the biologically available fraction of circulating estradiol by reducing plasma
concentration of sex hormone binding globulin (SHBG).102 Low plasma SHBG levels are
associated with insulin resistance103, 104 and other components of MS.105, 106 Second, adipose
tissue produces two adipokines (cytokine-like factors), leptin and adiponectin, that affect breast
cancer biology.107 Higher plasma leptin levels are associated with obesity,54, 57, 108 insulin
resistance,109, 110 and MS.111, 112 Leptin stimulates human breast cancer cell lines, whereas
adiponectin acts protectively, inhibiting the growth of these cell lines.57, 107, 113 Obesity is
associated with reduced adiponectin levels.114 Third, insulin has been shown to have a mitogenic
effect upon breast cancer cells in vitro through several mechanisms.57 It can act synergistically
with estradiol and stimulate proliferation of the cell line.115 Insulin can also lower SHBG
production,116 thereby increasing biologically available estradiol. Moreover, low serum HDL-C
concentrations indicate higher circulating bioactive estrogen levels, which in turn may stimulate
target breast tissue.76
The increasing prevalence of MS, and its association with breast cancer, among other comorbidities, point toward the critical need to develop public health strategies to manage MS.
Given the increasingly large global burden of metabolic risk factors, even a small association
with breast cancer can have a substantial public health impact. Risk assessment tools can be
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developed that incorporate MS as a risk factor for breast cancer. Healthcare providers will then
be better equipped to identify high-risk women for primary and secondary prevention.
This study has several strengths. First, to the best of our knowledge, this is the first
systematic review and meta-analysis to examine the association between MS and risk of breast
cancer in all adult women. The analysis incorporates all women, and a sub-analysis of postmenopausal women. The overlapping meta-analysis on metabolic syndrome and breast cancer
was confined to post-menopausal women only.10 Second, a number of other analyses were
performed that strengthened the robustness of findings. Third, the results of this study provide
direction for future research on this topic.
This study also has several potential limitations. These include (1) the different methods
used to assess exposure, identify cancer, control for confounders, and define MS, (2) limiting
studies to those published in English, which may have led to inflated results,117 (3) the relatively
small number of studies that met the inclusion criteria, (4) the inability of some studies to
provide raw data for calculating the RR, (5) the different study designs employed, and (6) the
varied populations studied.
In order to inform and undergird a biological rationale for the observed positive
association between MS and breast cancer risk in adult females, future studies should consist of
analyses based on a standard definition of MS and employ objective and standard biomarkers for
assessing each MS component. In addition, adjustments for all important potential confounders
need to be made. It would be helpful if future studies examined the relationship between MS and
breast cancer risk separately in perimenopausal and premenopausal women since breast cancer in
women may be estrogen-independent. Along those lines, not all studies adjusted for hormone
replacement therapy, a potential confounder. Future studies should report this information.
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Furthermore, future research needs to examine in situ and invasive cancers separately in relation
to metabolic syndrome. Finally, a focus on obese women with respect to MS and breast cancer
seems appropriate.
In conclusion, the overall results of this meta-analysis suggest that there is a modest
positive association between MS and risk of breast cancer in adult females.
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Tables and Figures
The working tables and figures can be found in Appendix A.
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CHAPTER 3. ASSOCIATION BETWEEN INDIVIDUAL AND COMBINED
METABOLIC RISK FACTORS AND CANCER RISK
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3.1

Abstract

Introduction
Cancer is the second most common cause of death in the United States. A third of the
cancer burden is estimated to be associated with metabolic risk factors (MRFs), such as obesity,
high blood glucose, hypertension, and dyslipidemia. However, studies have shown inconsistent
results for the association between these MRFs and cancer risk. The aim of this study was to
examine whether MRFs, either individually or in combination, were associated with the
subsequent risk of overall and selected site-specific cancers of the breast, digestive system, and
lung.
Methods
Data were derived from the NHANES I Epidemiologic Follow-up Study, and comprised
participants ages 25 to 74 years at baseline. Multivariable Cox proportional hazards regression
models were fitted to assess the association between individual and combined MRFs (obesity,
high blood pressure, high total serum cholesterol, and diabetes) and cancer incidence. Analyses
were adjusted for age, race, education, family income, physical activity, smoking status, and
family history of cancer, and stratified by age and gender. All analyses incorporated the complex
sample design and sample weights in order to generate national estimates.
Results
Diabetes, high BP, and the presence of a combination of three or four MRFs were
associated with higher breast cancer risk among postmenopausal women. Obesity in males less
than 50 years of age elevated the risk of digestive cancer.
Conclusion

39

In this large, prospective cohort study, MRFs, either individually or aggregated, were not
consistently associated with cancer risk in either men or women. The association of individual
and combined MRFs was stronger with postmenopausal breast cancer risk.
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3.2

Introduction
The “plague of our generation,”1 cancer is the second most common cause of death in the

United States. The American Cancer Society estimates 1.7 million new cancer cases in 2013.2
Cancer incidence rates per 100,000 persons (age-adjusted to the 2000 US standard population)
for 1995-2009 were 550.7 and 419.3 for males and females, respectively.2
Lifestyle factors, such as diet, obesity, physical activity, and smoking, play a significant
role in carcinogenesis. Approximately half of the cancer burden can be prevented or significantly
reduced by modifying lifestyle factors.3, 4 Lifestyle factors can generate metabolic abnormalities
that include overweight and obesity, and high blood pressure, cholesterol, and blood glucose.
Each of the aforementioned abnormalities has been separately implicated as a metabolic
risk factor (MRF) for cancer.5-25 Comprehensive reviews provide adequate evidence of an
association between obesity and several cancers in both men and women.14, 15, 17, 18, 26-28
Similarly, epidemiologic studies and reviews show that individuals with diabetes are at a higher
risk for most cancers, although the association is unclear for prostate and lung cancers.7, 12, 13, 16,
19, 29-32

Elevated blood pressure is also associated with several cancers, although the results are

inconsistent across studies.7, 10, 25 Results for the association between total serum cholesterol and
cancer are similarly inconclusive.33
Research indicates that the risk for heart disease and stroke increases with number of
MRFs.34, 35 A few studies have also indicated a similar pattern of increased risk for certain types
of cancer from combined MRFs.6-10, 20-23, 36-38 A combination of three or more of the MRFs is
generally termed as metabolic syndrome.39 It is estimated to be prevalent in a third of US
adults.40 A meta-analysis on risk of various cancers found that metabolic syndrome elevated the
risk for liver, colon, colorectal, pancreatic, thyroid, rectal, bladder, and prostate cancers in men,
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and endometrial, pancreatic, breast, rectal, liver, colorectal, colon, and ovarian cancers in
women.6
Each individual MRF can promote cancer through an independent biological mechanism.
In turn, these mechanisms can complement each other, and act additively to promote cancer
development. MRFs, functioning through various mechanisms, including increased
inflammatory markers, such as tumor necrosis factor-alpha and interleuken-6, increased
adipokines such as leptin, and decreased adiponectin, increased levels of free fatty acids and
triglycerides, insulin resistance, increased insulin-like growth factor-1, and increased oxidative
stress, can cause angiogenesis, cell migration, mitogenesis, and DNA damage.41-43
The prevalence of MRFs is high, and continues to rise.44 At the same time, there is
epidemiologic evidence of the association of MRFs with several cancers. Moreover, there are
few animal studies supporting the biological role of MRFs in cancer development and
progression. However, results from studies examining the association between individual and
combined MRFs and overall cancer are inconsistent. Therefore, this study examined the
association of MRFs (obesity, high blood pressure, high total serum cholesterol, and diabetes),
individually and in combination, and subsequent risk of overall and site-specific cancers of the
breast, digestive system, and lung.
3.3

Methods
3.3.1

Data Source and Study Population: Data were derived from the NHANES I

Epidemiologic Follow-up Study (NHEFS). The NHEFS is a national, multi-stage, stratified
probability sample of the non-institutionalized, civilian population in the U.S.45 It includes
participants from the NHANES I (National Health and Nutrition Examination Survey I) cohort
aged 25-74 years who completed a medical examination at baseline (1971-75). Participants were
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followed-up in 1982-84, 1986, 1987, and 1992. Only 5% of the original NHEFS sample was lost
through attrition.46
Baseline data were acquired by merging five NHANES I datasets on anthropometry,
biochemistry, medical history, medical needs, and medical examination. Since the NHEFS
follow-up was conducted for participants aged ≥ 25 years and ≤ 74 years at the time of NHANES
I interview, only this group was retained for the analysis. Cancer status was determined by
merging data from each of the 1982-84, 1986, 1987, and 1992 surveys, in addition to the NHEFS
vital statistics data.
The status variable, incident cancer cases, was defined using the International
Classification of Diseases-9th revision (ICD-9), codes 140-208, excluding ICD-173 (skin
cancer), and were followed up through interview and death certificate data. All cancer cases
since the baseline period were obtained from the first, second and third diagnoses of cancer,
along with their location (cancer-site). Skin cancer cases were not included among total cancer
cases, since their etiology is different and does not involve MRFs. For subjects with multiple
cancers, only the first occurring non-skin cancer was included. Year of death was used for cancer
incidence if a death certificate was the only source of cancer information.
Study participants were considered to be at risk for cancer from their date of first
examination until date of diagnosis of cancer, or death, or termination of follow-up, whichever
occurred first. Event times were censored for participants who had not developed cancer by the
end of follow-up or died from non-cancer causes.
A total of 14,407 persons from the NHANES dataset were followed up until 1993. Of
these, 684 had a cancer diagnosis at baseline (determined from the question: Has a doctor ever
told you that you have malignant tumor or growth?) or who died in the same year of examination
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and were excluded from analysis. In order to reduce the possibility of reverse causation, another
146 who developed cancer in the first two years of the study were excluded from analysis.
Participants with missing values on cancer status (n = 2,310), and on the covariates in the
multivariable model (n=573) were also excluded from the analysis. The final sample was 10,694
persons who were cancer-free at the beginning of their study period.
Information on the following predictor variables was obtained from the baseline
examination: obesity, assessed as body mass index in kg/m2; resting systolic (SBP) and diastolic
(DBP) blood pressure, measured as continuous variables in mmHg; total serum cholesterol,
measured as continuous variable in mg/dL; and self-reported diabetes, coded as a dichotomous
variable. Resting SBP and DBP were measured by a physician using a sphygmomanometer at the
beginning of the physical examination while the subject was in a sitting position, as consistent
with American Heart Association guidelines.47 All of these readings were retrieved from
NHANES I medical exam questionnaire. Total serum cholesterol was assessed using a semiautomated instrument in the Centers for Disease Control and Prevention's lipid standardization
laboratory. Information on diabetes was gathered from NHANES I medical history questionnaire
(Has a doctor ever told you had diabetes?) or from NHANES I healthcare needs questionnaire
(Did a doctor tell you had diabetes? or, do you take any diabetes medicine or insulin?).
Analyses were adjusted for the following potentially confounding variables: age, race,
education, family income, physical activity, smoking status, and family history of cancer. The
baseline medical history questionnaire provided information on age, race, education, family
income, and physical activity. At baseline, information on smoking status was very limited, and
information on family history of cancer was not collected. Therefore, smoking information was
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combined from the baseline and 1982 surveys, and information on family history of cancer was
derived from the latter survey.48-51
3.3.2 Statistical analysis
Multivariable Cox proportional hazards regression models, with time since measurement
as the time variable, and incident cancer cases as study events, were fitted to obtain hazard ratios
of cancer incidence from MRFs. The model accounted for differential entry and exit times
among the NHEFS participants. A time-interaction test was conducted with individual and
combined MRFs in the full model with overall cancer to check whether the assumption of
proportionality of hazard ratios over time was met.
Metabolic risk factors were classified as: (1) obesity: BMI≥ 30 kg/m2; (2) high blood
pressure: systolic BP ≥ 140 mm/Hg and/or diastolic BP ≥ 90 mm/Hg); (3) high cholesterol: total
serum cholesterol ≥ 240 mg/dL; and (4) diabetes: presence or absence of diabetes. The effect of
individual MRF was assessed relative to the absence of that risk factor.
Analyses were adjusted for the following potential confounding variables: age, sex, race
(white versus other), education (high school or less vs. above high school), family income
(<$5,000, $5,000 to <$15,000, and >=$15,000, based on the poverty line for 1971-75, which was
set at or below $5,000 as the annual income for a household of four members), physical activity
(moderately active or very active vs. quite inactive), smoking (smoked 100 cigarettes in one's
lifetime), and family history of cancer (dichotomous). In the NHANES I dataset, race was
classified as white, black, or other at baseline. However, for this study, the latter two categories
were combined and classified as nonwhite due to small numbers.48
Age was included in all models as an independent, continuous variable. In addition,
analyses were further stratified by age categorized as <50 and ≥ 50 years as at baseline. The
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rationale for this dichotomization was based on previous research that showed that adults 50
years and older bear the greatest cancer burden, with the largest proportion of cancer being
diagnosed in this age group.52 Another consideration was the biological changes, especially in
women, which occur around age 50. In addition to age, analyses were also stratified by gender.
Besides examining the association between individual MRFs and cancer risk, a second
analysis assessed the combined effect of MRFs on the risk of overall cancer. An additive
summary of MRF scores was created by combining the individual MRFs. A score of three was
assigned to participants with three or more MRFs. The summary score ranged from 0 (no MRF,
the referent category) to 3 (three or four risk factors). Analyses were adjusted for the following
potential confounders; age, race, education, family income, physical activity, smoking, and
family history of cancer, and stratified by gender and dichotomized age.
Site-specific cancer (breast, digestive, and lung) were examined separately in evaluating
an association between individual MRFs as well as the combined MRF score, and cancer risk.
Cancers of the digestive system included those of the alimentary canal below the neck (i.e.,
esophagus, stomach, small and large intestines) and key digestive organs (i.e., pancreas, liver,
and gallbladder).
In order to test the robustness of results, three different sensitivity analyses were
conducted. Analysis one included all years of cancer incidence data after the baseline exam;
analysis two excluded persons with missing data for diabetes; and analysis three was conducted
with continuous variables for BMI, BP, and cholesterol.
All data were analyzed using the complex samples module in IBM SPSS Statistics for
Windows, version 21.0 (Armonk, NY: IBM Corp). These analyses incorporated the complex
sample design and sample weights in order to produce national estimates.53
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3.4

Results
Time-interaction test with individual and combined MRFs in the full model with overall

cancer showed that the assumption of proportional hazards was not violated in the Cox
proportional hazards regression analyses. Table 1 presents the baseline characteristics of the
study population, incorporating the sampling weights and design specifications. Mean age at
baseline was 48.8 years. Among 10,694 persons followed-up between 1971 and 1993, 59% were
female, and most were white. Over a quarter of the sample had an annual family income below
poverty level, and about three quarters had an education less than college. Most participants
reported being moderately or very active in their non-recreational activity, and over half had
smoked at least 100 cigarettes during their lifetime. A third of the participants reported having a
family history of cancer. About 16.6% were obese, a little less than half had high BP, a third had
high cholesterol, and half of the sample had one or more MRFs.
Tables 2 and 3 present the association between individual MRFs and cancer risk among
males and females, respectively, after adjusting for potential confounding factors, and stratifying
by age. Individual MRFs were not significantly associated with cancer risk in males in the
multivariable Cox proportional hazards regression analyses, after controlling for age, race,
education, family income, physical activity, smoking, and family history (Table 2). A decreased
risk of overall cancer was observed among obese women 50 years of age and older (Table 3).
High total cholesterol elevated the risk of overall cancer in older women. No association was
observed in either gender between combined MRFs and overall cancer risk (Tables 4 and 5).
Tables 6 and 7 present the association of individual and combined MRFs respectively
with breast cancer risk in all women and postmenopausal women. High BP, diabetes, and
presence of a combination of three or four MRFs were associated with elevated breast cancer
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risk in postmenopausal women. Obesity in males elevated the risk of digestive cancer (Table 8).
Presence of a single MRF in women was associated with reduced risk of digestive cancer (Table
9). There was no association of MRFs with lung cancer in either gender (Tables 10 and 11).
Results were consistent with the main analysis in all sensitivity analyses. However, two
associations in the main analysis (high cholesterol with increased overall cancer risk, and obesity
with reduced overall cancer risk in older women) were not observed in other sensitivity analyses.
3.5

Discussion
In this large, prospective cohort study, MRFs, either individually or in the aggregate,

were not consistently associated with cancer risk in either gender. Overall, diabetes, high BP, and
the presence of a combination of three or four MRFs were associated with higher breast cancer
risk among postmenopausal women. Obesity in males less than 50 elevated the risk of digestive
cancer.
Study results show an association between diabetes and increased risk of breast cancer in
postmenopausal women. A meta-analysis on diabetes and breast cancer showed that among
postmenopausal women, diabetes was associated with a 16% increased risk of breast cancer.16
Similarly, another recent meta-analysis showed a significant positive association of high blood
pressure and high glucose/diabetes with postmenopausal breast cancer.8 Diabetes is frequently
associated with insulin resistance, increased circulating concentrations of insulin, and insulin-like
growth factors. Studies have shown insulin has mitogenic effects on breast tissue.54 In addition,
insulin inhibits the production of sex hormone-binding globulin, resulting in an increase in
bioavailable estradiol. Increased estradiol levels have been associated with the risk of developing
breast cancer.16, 55
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The finding that postmenopausal women with high BP were at an increased risk of breast
cancer is also supported by the recent meta-analysis on breast cancer risk in postmenopausal
women.8 Cancer and hypertension are both characterized by the proliferation of smooth muscle
cells.56 Another hypothesis indicates abnormalities of carcinogen binding to DNA in
lymphocytes of hypertensive women.57
The results showed a decreased risk of overall cancer from obesity, and an elevated risk
from high total cholesterol in women 50 years of age or older. However, in the sensitivity
analyses, these two results were not supported. Epidemiologic evidence suggests obesity is
associated with increased risk of site-specific cancers in women, such as cancers of
postmenopausal breast, esophagus, pancreas, endometrium, ovary, thyroid, and kidney.5, 15, 58-60
The question regarding the association between total cholesterol and cancer risk remains
unresolved in literature.61
When combined MRFs were examined, postmenopausal women with three or four MRFs
were observed to be at a higher risk of breast cancer. A recent meta-analysis showed that the
combined effect of MRFs on increased risk for postmenopausal breast cancer was greater than
that of individual MRFs.8 A combination of MRFs may activate different molecular pathways
through metabolic, endocrine, and immune cell changes, which can result in breast
tumorigenesis.62
Among men, the only significant association observed was between obesity and elevated
risk of digestive cancer. Other studies have also observed a similar association between
overweight/ obesity and digestive cancers, such as pancreatic63, 64 and colorectal cancers30 in
men. There is also an elevated risk of adenocarcinoma of the esophagus and gastric cardia with
increasing BMI.65 In obese persons, there is an increase in free fatty acids, cytokines, and
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hormones, resulting in increased insulin levels and insulin-like growth factor. High levels of
insulin or insulin-like growth factors can promote digestive cancers by promoting cellular
proliferation and inhibiting apoptosis.63
Several complex biological mechanisms have been proposed to show that MRFs promote
carcinogenesis. The prevalence of hyper-insulinemia and insulin resistance is higher in obese
individuals. Hyper-insulinemia reduces the production of insulin-like growth factor (IGF)
protein, resulting in increased bioavailability of IGF-1.30 IGF-1 may promote tumor
development by stimulating cell proliferation and inhibiting apoptosis. Increased circulating
insulin can reduce the levels of sex-hormone-binding-globulin, thereby increasing endogenous
sex-steroid levels.30 Breast, endometrial, and colorectal cancers may be affected by this
mechanism.66 Another carcinogenic mechanism involves cytokines. Increased adiposity raises
cytokine production in obese women, which in turn can induce estradiol production.41 Estradiol
is a strong growth factor for breast and endometrial cancers. Leptin, another adipocyte-specific
hormone, is directly related to adiposity and insulin resistance. It has direct stimulatory effects on
cancer cells and may serve as an important link between obesity and carcinogenesis.41
Study results show the association of MRFs with overall and site-specific cancers varies
by gender. These differences in the association between MRFs and cancer can arise for several
reasons. Animal studies suggest that production of a protein, interleukin-6, which promotes
inflammation, is linked to a higher incidence of liver cancer in men than in women.67
The current study has several potential limitations. For example, blood glucose levels
were not measured directly, but rather, a self-reported diagnosis of diabetes indexed high levels.
In addition, while total serum cholesterol levels were measured directly, there were no separate
measures for triglycerides, or low and high-density lipoprotein cholesterol levels (LDL and
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HDL). This may be important, since previous research has shown that high HDL may be
inversely associated with site-specific and overall cancer.68 However, a systematic review with
meta-analysis showed no association between triglyceride or HDL levels and such site-specific
cancers as colorectal cancer.9 Although models were adjusted for race, stratified analysis could
not be performed due to small sample size for races other than white. For this reason, nonwhite
were combined into one category, although studies have observed racial differences in MRFs.69
Analyses on lung and digestive cancer could not be stratified by age because of small number of
cancer cases.
This study has several strengths. For example, data were derived using a strong
longitudinal cohort study design with high follow-up rates. Specifically, 96% of the study
population was successfully traced at some point through the 1992 follow-up.46 It is a large,
nationally representative sample of the US population. All analyses utilized complex sample
survey design for results representative of the population. In addition, self-report bias tended to
be minimized because MRFs, such as total serum cholesterol, as well as blood pressure and
anthropometry (BMI), were based on body measurements and laboratory data.
In conclusion, MRFs, either individually or in the aggregate, were not consistently
associated with cancer risk in either gender in this large, prospective cohort study. The
association of individual and combined MRFs was stronger with postmenopausal breast cancer
risk.
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CHAPTER 4. ASSOCIATION BETWEEN METABOLIC RISK FACTORS AND AGE
AT CANCER ONSET
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4.1

Abstract

Introduction
Cancer is the second most common cause of death in the United States. There is evidence
that components of metabolic syndrome, a cluster of pathophysiological disorders comprising
obesity, insulin resistance, hypertension, and dyslipidemia, elevate cancer risk. However, there is
scant literature on the association between the components of metabolic syndrome and age at
cancer onset. The aim of this study is to examine whether metabolic risk factors (MRFs), either
individually or in combination, are associated with age at onset of all-site cancer, and cancer of
the breast, digestive system, and lung, respectively.
Methods
Data were derived from the NHANES I Epidemiologic Follow-up Study, and comprised
participants ages 25 to 74 years at baseline. The outcome variable was age at cancer onset, and
the primary metabolic risk factors were obesity, high blood pressure, high total serum
cholesterol, and diabetes. Analyses were adjusted for age, race, education, family income,
physical activity, smoking status, and family history of cancer, and stratified by age and gender.
Multiple linear regression analyses, using the general linear model, were conducted to assess the
relationship between MRFs and age at cancer onset. All analyses incorporated the complex
sample design and sample weights to produce national estimates.
Results
Study results showed an increased risk of diabetes associated with earlier age at (a)
cancer onset in younger and older males, (b) cancer onset in older females, (c) postmenopausal
breast cancer onset, and (d) lung cancer onset in both genders. Presence of a combination of
three or four MRFs was associated with earlier age at onset of: (a) overall cancer in women 50
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years and older, (b) postmenopausal breast cancer, (c) digestive cancer in females, and (d) lung
cancer in males.
Conclusion
Overall, diabetes and a combination of three or four MRFs were found to be associated
with earlier age at onset of overall and site-specific cancers. The association with combined
MRFs was stronger in women. Future research needs to determine the underlying mechanisms
that may predispose people with metabolic abnormalities to cancer.
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4.2

Introduction
Accounting for one in four deaths, cancer is the second most common cause of death in

the United States (U.S.) after heart disease.1 The National Cancer Institute estimates 1.7 million
new cancer cases in 2013.2 Annualized cancer incidence rates for 2006-2010 were 535.9 and
411.2 per 100,000 males and females, respectively.2 The World Cancer Research Fund estimates
that 25-33% of new cancer cases in the U.S. in 2013 are related to behavioral and lifestyle
factors such as overweight or obesity, physical inactivity, and poor nutrition.3
Metabolic syndrome is a cluster of pathophysiological disorders comprising central
obesity, insulin resistance, hypertension, and dyslipidemia. Based on the application of various
definitions of metabolic syndrome, an estimated one-third of US adults are afflicted by it.4 There
is substantial evidence that this cluster of metabolic risk factors accelerates onset of
cardiovascular diseases.5, 6 In addition, studies conducted over the past decade indicate that the
combined metabolic risk factors (MRFs) are positively and significantly associated with overall
cancer7 and site-specific cancers, including breast cancer,7-20 digestive cancer,21 liver cancer,14, 22
prostate cancer,23-26 colorectal cancer,27-32 and endometrial cancer.33 A recent meta-analysis of
prospective cohort studies concluded that metabolic syndrome is associated with an elevated
overall cancer risk among adults.34 This study found a significant association between metabolic
syndrome and increased risk of liver, colorectal, and bladder cancers in men, and endometrial,
pancreatic, postmenopausal breast, and colorectal cancers in women.34
Few epidemiologic studies have reported associations between MRFs and age at cancer
onset. A large cohort study found that obesity in adulthood was linked to increased cancer
mortality risk.35 Overweight and obesity during early adulthood were also associated with earlier
age at onset in obesity-related cancers, such as pancreatic cancer.36 In this large case-control
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study, obesity from the ages of 20 to 29 years was associated with earlier age of cancer onset by
seven years.36 A nested case-control study suggested hypertensive adults were at risk of
developing cancer ten years earlier than normotensives.37
A paucity of literature exists on the association between individual and combined MRFs
and age at cancer onset. Animal studies suggest that mechanisms, which prevent metabolic
abnormalities, by reducing serum insulin-like growth factor-1 or androgen concentrations, may
delay the growth and progression of breast and prostate cancers.38 Another animal study found
that mammary tumors developed earlier in diet-induced obese rats than in lean rats, thus
supporting the role of hormones and adipokines (produced by adipose tissue) in cell proliferation
and carcinogenesis.39
Given the associations between MRFs and several cancers, as suggested by
epidemiologic human studies, as well as animal studies, an important research question is
whether MRFs are associated with earlier age at cancer onset. This question is important for at
least four reasons. First, age at onset of certain cancers is temporally decreasing. A populationbased study, using data for England and Wales covering the period 1971-1999, found earlier age
at onset of breast, cervical, and prostate cancer.40 Second, earlier cancer onset signifies shorter
life expectancy, and therefore, major loss of potential years of life.41 Third, younger cancer
patients are likely to have more aggressive cancers, less favorable prognosis, and poorer
outcomes than older patients.41-43 Fourth, earlier age at cancer onset in a family may increase the
lifetime risk of developing cancer in the next generation.44, 45 Therefore, it is important to
understand the association between metabolic syndrome and age at cancer onset so that
appropriate guidelines can be developed for cancer screening, prevention, and treatment.
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This study assessed the influence of MRFs (obesity, high blood pressure, high total serum
cholesterol, and diabetes), and their combination, on age at onset of all-site cancer, and cancer of
the breast, digestive system, and lung.
4.3

Methods
4.3.1

Data Source and Study Population: Data were derived from a cohort study, the

NHANES I Epidemiologic Follow-up Study (NHEFS).46 The NHEFS is a national multi-stage,
stratified probability sample of the non-institutionalized, civilian population in the US. It
includes participants from the NHANES I cohort, who were ages 25 to 74 years, and completed a
medical examination at baseline (1971-75).46 Participants were followed-up in 1982-84, 1986,
1987, and 1992. Only 5% of the original NHEFS sample was lost through attrition.47
Baseline data were acquired by merging five NHANES I data files on anthropometry,
biochemistry, medical history, medical needs, and medical examination. Since the NHEFS
follow-up was conducted for participants aged ≥ 25 years and ≤ 74 years at time of NHANES I
interview, only this group was retained for the analysis. Cancer status was determined by
merging data from each of the 1982-84, 1986, 1987, and 1992 surveys, in addition to the NHEFS
vital statistics data.
The outcome variable was age at cancer onset. Cancer cases were defined using the
International Classification of Diseases-9th revision (ICD-9), codes 140-208, excluding ICD-173
(skin cancer), and were followed up through interview and death certificate data. All the cancer
cases occurring after the baseline period and reported in 1982-84, 1986, 1987, and 1992
interviews, were obtained from the first, second and third diagnoses of cancer along with their
location (cancer-site). Skin cancer cases were not included among total cancer cases since the
mechanism of skin cancer development is different and does not involve metabolic risk factors.
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For subjects with multiple cancers, only the first occurring non-skin cancer was included. All
cancer cases were aligned with year of diagnosis. The final outcome variable, age at cancer
onset, was computed by subtracting birth year from year of cancer diagnosis, and was computed
for overall cancer and for cancer of the breast, digestive system, and lung, respectively.
A total of 14,407 persons from the NHANES I dataset were followed up in 1982-84. Of
these, 684 had a cancer diagnosis at baseline (determined from the question "Has a doctor ever
told you that you have malignant tumor or growth?") or who died within the year of baseline
interview and were excluded from the analysis. In order to reduce the possibility of reverse
causation, another 146 who developed cancer in the first two years of the study were excluded
from analysis. Among those who were followed, 1,837 persons (13.5%) were diagnosed with
cancer during the study period. Participants with missing data (n = 101) on covariates, which
were included in the multivariable model, were also excluded from the analysis. The final sample
was 1,736.
Information on the following predictor variables was obtained from the baseline
examination: obesity, assessed as body mass index in kg/m2, resting systolic (SBP) and diastolic
(DBP) blood pressure, measured as continuous variables in mmHg, total serum cholesterol,
measured as continuous variable in mg/dL, and self-reported diabetes, coded as a dichotomous
variable. Consistent with American Heart Association guidelines, resting SBP and DBP were
measured by a physician using a sphygmomanometer at the beginning of the physical
examination while the subject was in a sitting position.48 All of these readings were retrieved
from the NHANES I medical exam questionnaire. Total serum cholesterol was assessed using a
semi-automated instrument in the Centers for Disease Control and Prevention's lipid
standardization laboratory. Information on diabetes was gathered from the NHANES I medical
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history questionnaire (Has a doctor ever told you had diabetes?) or from the NHANES I
healthcare needs questionnaire (Did a doctor tell you had diabetes? or, do you take any diabetes
medicine or insulin?).
Analyses were adjusted for the following potentially confounding variables: age, race,
education, family income, physical activity, smoking status, and family history of cancer. The
baseline medical history questionnaire provided information on age, race, education, family
income, and physical activity. At baseline, information on smoking status was very limited, and
information on family history of cancer was not collected. Therefore, information on smoking
status was combined from the baseline and 1982 surveys, and information on family history of
cancer was derived from the latter survey.49-52
4.3.2

Statistical Analysis

Multiple linear regression analyses, using the general linear model, were used to assess
the relationship between MRFs and age at cancer diagnosis.36, 53 The severity of multicollinearity
for each variable was assessed by calculation of the variance inflation factor. All data were
analyzed using the complex samples module in IBM SPSS Statistics for Windows, version 21.0
(Armonk, NY: IBM Corp). All analyses incorporated the complex sample design and sample
weights in order to produce national estimates.
The outcome variable, age at cancer onset, was computed by subtracting birth year from
year of cancer diagnosis, and analyzed as a continuous variable. Metabolic risk factors were
classified as: (1) obesity: BMI≥ 30 kg/m2; (2) high blood pressure: systolic BP ≥ 140 mm/Hg
and/or diastolic BP ≥ 90 mm/Hg); (3) high cholesterol: total serum cholesterol ≥ 240 mg/dL; and
(4) diabetes: presence or absence of diabetes. Multiple linear regression models were used to
examine the association between MRFs (obesity, high BP, high cholesterol, and diabetes) and
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age at cancer diagnosis.36, 53 The effect of individual MRF was assessed relative to the absence of
that risk factor.
Analyses were adjusted for the following potentially confounding variables: age, race
(whites versus others), education (high school or less vs. above high school), family income
(<$5,000, $5,000 to $14,999, and ≥$15,000, based on the poverty line for 1971-75 that was set at
or below $5,000 as the annual income for a household of four members), physical activity
(moderately active or very active vs. quite inactive), smoking (smoked 100 cigarettes in one's
lifetime), and family history of cancer (dichotomous). In the NHANES I dataset, race was
classified as white, black, or other at baseline. However, for this study, the latter two categories
were combined and classified as nonwhite due to small number.50
Age was included in all models as an independent, continuous variable. In addition,
analyses were further stratified by age categorized as < 50 and ≥ 50 years as at baseline. The
rationale for this dichotomization was based on previous research that has shown that adults 50
years or older bear the greatest burden of cancer, with the largest proportions of cancers being
diagnosed in this age group.54 Moreover, there are biological changes, especially in women,
around age 50. Posthoc, all analyses were also stratified by gender after determining that the
association between individual MRFs and age at cancer onset differed by gender.55, 56
Besides examining the association between individual MRFS and age at cancer onset,
analyses were performed to assess the combined effect of MRFs on age at cancer onset. An
additive summary of MRF scores was created by combining the individual MRFs. A score of
three was assigned to participants with three or four MRFs. The summary score ranged from 0
(no MRF, the referent category) to 3 (three or four risk factors). Analyses were adjusted for the
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following potential confounders: age, race, education, family income, physical activity, smoking,
and family history of cancer, and stratified by gender and age (< 50 and ≥ 50 years of age).
Site-specific cancers (breast, digestive, and lung cancers) were examined separately in
evaluating an association between individual MRFs as well as the combined MRF score, and age
at cancer onset. Cancers of the digestive system included those of the alimentary canal below the
neck (e.g., esophagus, stomach, small and large intestines) and key digestive organs (i.e.,
pancreas, liver, and gallbladder).
4.4

Results
Table 1 presents the baseline characteristics of the study population. Among the 1,736

persons diagnosed with cancer between 1973 and 1992, approximately half were women and
most were white. Almost a third of the sample had an annual family income below the poverty
level, while more than three fourths had a high school education or less. About 17% were obese,
over half had hypertension, and more than a third had high total cholesterol. Very few
participants had three or four MRFs.
Table 2 presents the association between individual MRFs and age at cancer onset among
males, after adjusting for potential confounders, and stratifying by age and gender. Among males
less than 50 years of age at baseline, obesity was associated with later age at cancer onset. Mean
age at cancer onset for obese men who were younger than age 50 was (mean + SE) 55.8 + 1.52
years compared to 53.1 + 1.32 years for those who were not obese. Diabetes was associated with
earlier age at cancer onset in younger males. Mean age at cancer onset for men with diabetes,
who were younger than age 50, was 52.2 + 2.16 years compared to 56.6 + 1.18 years for those
who did not have diabetes. Among males 50 years and older, diabetes was again associated with
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earlier age at cancer onset. Mean age at cancer onset for older men with diabetes was 68.1 + 1.42
years compared to 70.9 + 0.57 years for those who did not have diabetes.
Among women 50 years and older, diabetes was associated with earlier age at cancer
onset (Table 3). Mean age at cancer onset for older women with diabetes was 70.4 + 1.06 years
compared to 72.4 + 0.81 years for those who did not have diabetes.
Tables 4 and 5 present the association between the aggregate MRF score (ranging from 1
MRF to three or four MRFs, compared with the referent category of no MRF) and age at cancer
onset among males and females, respectively, after adjusting for potential confounders, and
stratifying by age. No significant association was observed among males Table 4). Among
women younger than 50 years of age, presence of three or four MRFs was associated with later
age at cancer onset (Table 5). Mean age at cancer onset for these women was 51.8 + 0.97 years
compared to 52.7 + 0.98 years for those who had no MRF. This association reversed in older
women. Presence of three or four MRFs in women 50 and older was associated with earlier age
at cancer onset. Mean age at cancer onset for older women with combined MRFs was 70.2 +
0.89 years compared to 72.9 + 1.03 years for those who had no MRF.
Table 6 presents the associations between individual MRFs and age at breast cancer onset
in all women, and in postmenopausal women. Diabetes was associated with earlier age at
postmenopausal breast cancer onset. Mean age at onset was 66.0 + 1.46 years compared to 68.7
+ 0.74 years for those who did not have diabetes. Presence of combined three or four MRFs was
associated with earlier age at onset among all women and postmenopausal women (Table 7).
Mean age at cancer onset for all women with combined MRFs was 59.1 + 1.22 years compared
to 62.4 + 1.08 years for those who had no MRF. Among postmenopausal women with combined
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MRFs, mean age at cancer onset was 67.0 + 1.07 years compared to 70.9 + 1.52 years for those
who had no MRF.
Table 8 presents the associations between individual MRFs and age at digestive cancer
onset among males and females. No association was observed in any strata. Examining the
combined MRFs, presence of one, three or four MRFs was associated with earlier age at
digestive cancer onset among females (Table 9). Mean age at onset among females with three or
four MRFs was 68.5 + 1.25 years compared to 72.9 + 1.19 years for those who did not have any
MRF.
Table 10 presents the association between individual MRFs and age at lung cancer onset
among males and females. Overall, diabetes was associated with earlier age at onset among both
males and females. Mean age at lung cancer onset for males with diabetes was 58.7 + 1.77 years
compared to 66.1 + 0.90 years for those who did not have diabetes. Similarly, mean age at lung
cancer onset for females with diabetes was 62.9 + 1.78 years compared to 67.5 + 1.05 years for
those who did not have diabetes. When examining the combined MRFs, presence of three or four
MRFs in males was also associated with earlier age at lung cancer onset (Table 11). Mean age at
onset among males with three or four MRFs was 62.5 + 1.57 years compared to 66.2 + 1.25
years for those who did not have any MRF.
4.5

Discussion
The aim of this study was to examine whether MRFs and their combination were

associated with age at cancer onset. Since there are several definitions of metabolic syndrome,
and thus several possible combinations, the independent effect of each single component was
also examined.
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Study results show an increased risk of diabetes associated with earlier age at cancer
onset in younger and older males, and in older females. Diabetes was also associated with early
age at onset of postmenopausal breast cancer, and lung cancer in both genders. Epidemiologic
reviews and meta-analytic studies suggest that people with diabetes were at a higher risk for
overall cancer and cancers of several sites, such as liver, pancreas, endometrium, colon, rectum,
breast, and bladder.57, 58 Although several observational studies do not show an association
between diabetes and lung cancer, the Metabolic Syndrome and Cancer project that comprises
six large prospective cohorts found that a one millimole per liter increase in glucose levels in
men was associated with increased risk for incidence and mortality from cancer of lung, trachea,
and bronchus.59 Another cohort study found an increased risk for lung cancer mortality in
diabetic women.60
Study results also show that obesity was associated with later age at cancer onset in males
less than 50 years of age. While epidemiologic evidence suggests obesity is associated with an
increased risk of cancer in men,61 studies on the association between obesity and age at cancer
onset are scant.
Presence of a combination of three or four MRFs was associated with later age at cancer
onset among females less than 50 years of age. This association was reversed in older women.
Presence of three or four MRFs was associated with earlier age at onset of: (a) overall cancer in
women 50 and older, (b) postmenopausal breast cancer, (c) digestive cancer in females, and (d)
lung cancer in males. A meta-analysis found that metabolic syndrome was positively associated
with postmenopausal breast, endometrial, pancreatic, and colorectal cancers in women.34 A large
cohort study showed that metabolic syndrome was associated with increased liver and breast
cancer risk in women.14 Another cohort study concluded with a significant increase in breast
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cancer risk among older women with two or three MRFs, suggesting that the combined MRFs
may elevate breast cancer risk beyond a single MRF, such as obesity.62 However, studies on the
association between combined MRFs and age at cancer onset are lacking.
Studies have suggested potential biological mechanisms that link MRFs with various
cancers. In brief, through various mechanisms, including obesity, increased inflammatory
markers such as tumor necrosis factor - and interleuken-6, increased adipokines such as leptin
and decreased adiponectin, increased levels of free fatty acids and triglycerides, insulin
resistance, increased insulin-like growth factor-1, and increased oxidative stress, MRFs have
been shown to cause angiogenesis, cell migration, mitogenesis, and DNA damage.63 There is,
therefore, an emerging hypothesis that a combination of MRFs may be an important etiologic
factor for the onset of cancer.64
Gender differences in the association between MRFs and cancer can arise for several
reasons. Components of metabolic syndrome operate differently by gender.55, 56 Metabolic
hormones that control cell growth can elevate cancer risk in women, whereas obesity-related
hyperinsulinemia can increase the risk in men.65 Longitudinal studies show that the association
between metabolic syndrome and elevated cancer risk is stronger in women.14 Animal studies
have shown that obesity-related adipokines enhance cell proliferation and elevate breast cancer
risk.66
The current study has several potential limitations. For example, blood glucose levels
were not measured directly but rather, a self-reported diagnosis of diabetes was used as an
indicator of high levels. In addition, while total serum cholesterol levels were measured directly
and not self-reported, there were no separate measures for triglycerides, or low and high-density
lipoprotein cholesterol levels (LDL and HDL). This may be important since previous research
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has shown that high HDL may be inversely associated with site-specific and overall cancer,67
although others reported no association between triglyceride or HDL levels and such site-specific
cancers as colorectal cancer.32
Prior research has reported differences in age at cancer onset among different
racial/ethnic populations for overall and site-specific cancers.68, 69 However, while models were
adjusted for race, a stratified analysis could not be performed due to the small sample size for
races other than white. For this reason, nonwhite were combined into one category, although
studies show racial differences related to MRFs.70
This study has several strengths. For example, data for this study were derived from a
longitudinal cohort study design with high follow-up rates. Specifically, 96% of the study
population was successfully traced at some point through the 1992 follow-up.47 It is a large
nationally representative sample of the US population. In addition, self-report bias tended to be
minimized because MRFs, such as total serum cholesterol, as well as blood pressure and
anthropometry (BMI), were based on body measurements and laboratory data. All analyses
utilized complex sample survey design for results representative of the population.
In conclusion, diabetes and a combination of three or four MRFs were found to be
associated with earlier age at onset of overall and site-specific cancers. The association with
combined MRFs was stronger in women. Future research needs to determine the underlying
mechanisms that predispose people with metabolic abnormalities to cancer. To this end, it is
essential to examine the relationship among site-specific cancers, stratified by gender and race,
with detailed information on LDL and HDL cholesterol levels, abdominal and visceral adiposity,
blood glucose levels, time period of each abnormality, and medications and their period of use.

72

Reference List
(1) Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin
2013;63(1):11-30.
(2) Howlader N, Noone AM, Krapcho M, Garshell J, et al. SEER Cancer Statistics Review,
1975-2010. Bethesda, MD: National Cancer Institute; 2013.
(3) World Cancer Research Fund/American Institute for Cancer Research. Policy and Action
for Cancer Prevention. Food, Nutrition, and Physical Activity: a Global Perspective.
Washington DC: American Institute for Cancer Research; 2009.
(4) Ervin R. Prevalence of metabolic syndrome among adults 20 years of age and over, by
sex, age, race and ethnicity, and body mass index: United States, 2003-2006. National
health statistics reports; no. 13. Hyattsville, MD: National Center for Health Statistics;
2009.
(5) Mottillo S, Filion KB, Genest J et al. The metabolic syndrome and cardiovascular risk a
systematic review and meta-analysis. J Am Coll Cardiol 2010;56(14):1113-1132.
(6) Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a
meta-analysis. Am J Med 2006;119(10):812-819.
(7) Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer
2008;44(2):293-297.
(8) Agnoli C, Berrino F, Abagnato CA et al. Metabolic syndrome and postmenopausal breast
cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis
2010;20(1):41-48.
(9) Bjorge T, Lukanova A, Jonsson H et al. Metabolic syndrome and breast cancer in the mecan (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev
2010;19(7):1737-1745.
(10) Capasso I, Esposito E, Pentimalli F et al. Metabolic syndrome affects breast cancer risk
in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol
Ther 2011;10(12):1240-1243.
(11) Healy LA, Ryan AM, Carroll P et al. Metabolic syndrome, central obesity and insulin
resistance are associated with adverse pathological features in postmenopausal breast
cancer. Clin Oncol (R Coll Radiol ) 2010;22(4):281-288.
(12) Inoue M, Noda M, Kurahashi N et al. Impact of metabolic factors on subsequent cancer
risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer
Prev 2009;18(3):240-247.

73

(13) Kabat GC, Kim M, Chlebowski RT et al. A longitudinal study of the metabolic syndrome
and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev
2009;18(7):2046-2053.
(14) Osaki Y, Taniguchi S, Tahara A, Okamoto M, Kishimoto T. Metabolic syndrome and
incidence of liver and breast cancers in Japan. Cancer Epidemiol 2012;36(2):141-147.
(15) Porto LA, Lora KJ, Soares JC, Costa LO. Metabolic syndrome is an independent risk
factor for breast cancer. Arch Gynecol Obstet 2011;284(5):1271-1276.
(16) Rosato V, Bosetti C, Talamini R et al. Metabolic syndrome and the risk of breast cancer
in postmenopausal women. Ann Oncol 2011;22(12):2687-2692.
(17) Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast
cancer in African-American and white American women. Endocr Rev 2007;28(7):763777.
(18) Sinagra D, Amato C, Scarpilta AM et al. Metabolic syndrome and breast cancer risk. Eur
Rev Med Pharmacol Sci 2002;6(2-3):55-59.
(19) Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the
metabolic syndrome in breast cancer. Obes Rev 2007;8(5):395-408.
(20) Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the
current evidence. Am J Clin Nutr 2007;86(3):s823-s835.
(21) Matthews CE, Sui X, LaMonte MJ, Adams SA, Hebert JR, Blair SN. Metabolic
syndrome and risk of death from cancers of the digestive system. Metabolism
2010;59(8):1231-1239.
(22) Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic
syndrome increases the risk of primary liver cancer in the United States: a study in the
SEER-Medicare database. Hepatology 2011;54(2):463-471.
(23) Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT.
Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based
study. Cancer Epidemiol Biomarkers Prev 2004;13(10):1646-1650.
(24) Lund HL, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer
in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol
2006;164(8):769-774.
(25) Pelucchi C, Serraino D, Negri E et al. The metabolic syndrome and risk of prostate
cancer in Italy. Ann Epidemiol 2011;21(11):835-841.
(26) Esposito K, Chiodini P, Capuano A et al. Effect of metabolic syndrome and its
components on prostate cancer risk: Meta-analysis. J Endocrinol Invest 2013;36(2):132139.
74

(27) Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic
syndrome and risk of incident colorectal cancer. Cancer 2006;107(1):28-36.
(28) Chiu HM, Lin JT, Shun CT et al. Association of metabolic syndrome with proximal and
synchronous colorectal neoplasm. Clin Gastroenterol Hepatol 2007;5(2):221-229.
(29) Siddiqui AA. Metabolic syndrome and its association with colorectal cancer: a review.
Am J Med Sci 2011;341(3):227-231.
(30) Stocks T, Lukanova A, Johansson M et al. Components of the metabolic syndrome and
colorectal cancer risk; a prospective study. Int J Obes (Lond) 2008;32(2):304-314.
(31) Sturmer T, Buring JE, Lee IM, Gaziano JM, Glynn RJ. Metabolic abnormalities and risk
for colorectal cancer in the physicians' health study. Cancer Epidemiol Biomarkers Prev
2006;15(12):2391-2397.
(32) Esposito K, Chiodini P, Capuano A et al. Colorectal cancer association with metabolic
syndrome and its components: a systematic review with meta-analysis. Endocrine 2013.
(33) Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. Metabolic
syndrome and endometrial cancer: a meta-analysis. Endocrine 2013.
(34) Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of
cancer: a systematic review and meta-analysis. Diabetes Care 2012;35(11):2402-2411.
(35) Gray L, Lee IM, Sesso HD, Batty GD. Association of body mass index in early adulthood
and middle age with future site-specific cancer mortality: the Harvard Alumni Health
Study. Ann Oncol 2012;23(3):754-759.
(36) Li D, Morris JS, Liu J et al. Body mass index and risk, age of onset, and survival in
patients with pancreatic cancer. JAMA 2009;301(24):2553-2562.
(37) Xie L, Wu K, Xu N, Chen D, Chen J, Lu S. Hypertension is associated with a high risk of
cancer. J Hum Hypertens 1999;13(5):295-301.
(38) Zhou JR, Li L, Pan W. Dietary soy and tea combinations for prevention of breast and
prostate cancers by targeting metabolic syndrome elements in mice. Am J Clin Nutr
2007;86(3):s882-s888.
(39) Hakkak R, Holley AW, Macleod SL et al. Obesity promotes 7,12dimethylbenz(a)anthracene-induced mammary tumor development in female zucker rats.
Breast Cancer Res 2005;7(5):R627-R633.
(40) Newby JA, Busby CC, Howard CV, Platt MJ. The cancer incidence temporality index: an
index to show temporal changes in the age of onset of overall and specific cancer
(England and Wales, 1971-1999). Biomed Pharmacother 2007;61(10):623-630.

75

(41) Lee CH, Lee KW, Fang FM et al. The use of tobacco-free betel-quid in conjunction with
alcohol/tobacco impacts early-onset age and carcinoma distribution for upper
aerodigestive tract cancer. J Oral Pathol Med 2011;40(9):684-692.
(42) Ahn SH, Son BH, Kim SW et al. Poor outcome of hormone receptor-positive breast
cancer at very young age is due to tamoxifen resistance: nationwide survival data in
Korea--a report from the Korean Breast Cancer Society. J Clin Oncol 2007;25(17):23602368.
(43) Han W, Kang SY. Relationship between age at diagnosis and outcome of premenopausal
breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset
breast cancer. Breast Cancer Res Treat 2010;119(1):193-200.
(44) Brune KA, Lau B, Palmisano E et al. Importance of age of onset in pancreatic cancer
kindreds. J Natl Cancer Inst 2010;102(2):119-126.
(45) Hemminki K, Li X. Familial and second primary pancreatic cancers: a nationwide
epidemiologic study from Sweden. Int J Cancer 2003;103(4):525-530.
(46) National Center for Health Statistics. National Center for Health Statistics. NHANES I
Epidemiologic Followup Study (NHEFS) Public-Use Data Files. 2013.
(47) Cox CS, Mussolino ME, Rothwell ST, et al. Plan and operation of the NHANES I
Epidemiologic Followup Study 1992. National Center for Health Statistics; 1997. Report
No.: 1.
(48) Kirkendall WM, Burton AC, Epstein FH, Freis ED. Recommendations for human blood
pressure determination by sphygmomanometers. Circulation 1967;36(6):980-988.
(49) Schatzkin A, Jones DY, Hoover RN et al. Alcohol consumption and breast cancer in the
epidemiologic follow-up study of the first National Health and Nutrition Examination
Survey. N Engl J Med 1987;316(19):1169-1173.
(50) Albanes D, Blair A, Taylor PR. Physical activity and risk of cancer in the NHANES I
population. Am J Public Health 1989;79(6):744-750.
(51) Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer
incidence in a prospective study. Epidemiology 1994;5(2):138-146.
(52) Su LJ, Arab L. Alcohol consumption and risk of colon cancer: evidence from the national
health and nutrition examination survey I epidemiologic follow-up study. Nutr Cancer
2004;50(2):111-119.
(53) Zisman AL, Nickolov A, Brand RE, Gorchow A, Roy HK. Associations between the age
at diagnosis and location of colorectal cancer and the use of alcohol and tobacco:
implications for screening. Arch Intern Med 2006;166(6):629-634.

76

(54) United States Department of Health and Human Services, Centers for Disease Control
and Prevention, National Cancer Institute. National Program of Cancer Registries Early
Release Cancer Statistics: 1999-2010, WONDER On-line Database. 2013.
(55) Beigh SH, Jain S. Prevalence of metabolic syndrome and gender differences.
Bioinformation 2012;8(13):613-616.
(56) Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic
syndrome and their role for cardiovascular disease. Clin Res Cardiol 2006;95(3):136-147.
(57) Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the
epidemiological evidence. Cancer Sci 2013;104(1):9-14.
(58) Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat
Cancer 2009;16(4):1103-1123.
(59) Stocks T, Rapp K, Bjorge T et al. Blood glucose and risk of incident and fatal cancer in
the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts.
PLoS Med 2009;6(12):e1000201.
(60) Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and
cancer risk in Korean men and women. JAMA 2005;293(2):194-202.
(61) Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and
proposed mechanisms. Nat Rev Cancer 2004;4(8):579-591.
(62) Reeves KW, McLaughlin V, Fredman L, Ensrud K, Cauley JA. Components of metabolic
syndrome and risk of breast cancer by prognostic features in the study of osteoporotic
fractures cohort. Cancer Causes Control 2012;23(8):1241-1251.
(63) Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J
Pathol 2006;169(5):1505-1522.
(64) Zhou JR, Blackburn GL, Walker WA. Symposium introduction: metabolic syndrome and
the onset of cancer. Am J Clin Nutr 2007;86(3):s817-s819.
(65) Chesney ET, Davis SC, Duggan L, Natarajan S. Does metabolic syndrome increase risk
for certain cancers? American Journal for Nurse Practitioners 2010;14(4):25-32.
(66) Lautenbach A, Budde A, Wrann CD et al. Obesity and the associated mediators leptin,
estrogen and IGF-I enhance the cell proliferation and early tumorigenesis of breast cancer
cells. Nutr Cancer 2009;61(4):484-491.
(67) Ahn J, Lim U, Weinstein SJ et al. Prediagnostic total and high-density lipoprotein
cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 2009;18(11):28142821.

77

(68) Rose DP, Royak-Schaler R. Tumor biology and prognosis in black breast cancer patients:
a review. Cancer Detect Prev 2001;25(1):16-31.
(69) Karami S, Young HA, Henson DE. Earlier age at diagnosis: another dimension in cancer
disparity? Cancer Detect Prev 2007;31(1):29-34.
(70) DeBoer MD, Dong L, Gurka MJ. Racial/ethnic and sex differences in the relationship
between uric acid and metabolic syndrome in adolescents: an analysis of National Health
and Nutrition Survey 1999-2006. Metabolism 2012;61(4):554-561.

78

Tables
The working tables can be found in Appendix C.

79

CHAPTER 5. DISCUSSION
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5.1

Discussion
The three dissertation studies were conducted with the overall goal of examining the

association between individual and combined metabolic risk factors (MRFs) and subsequent risk
of overall and site-specific cancers of the breast, digestive system, and lung. This chapter
discusses the findings from the three studies, lists their strengths and limitations, and concludes
with a suggested future course of action.
5.2

Study 1 Discussion: Metabolic Syndrome is associated with increased breast cancer

risk: A systematic review with meta-analysis
The purpose of this aggregate data meta-analysis was to examine the association between
metabolic syndrome and the risk for breast cancer in adult females. Of the 291 studies screened,
47 underwent a full-text review, of which eight studies with nine independent cohorts met the
eligibility criteria. The overall results of this aggregate data meta-analysis show a modest
positive association between metabolic syndrome and breast cancer risk in adult females, with a
47% elevated risk for incident breast cancer for adult females with metabolic syndrome.
This finding is strengthened by the robustness of results from other analyses. These
include: (1) examination for publication bias, (2) influence analysis with each study deleted from
the model once, (3) deletion of the two case-control studies with odds ratios from the overall
model, (4) limiting the analysis to prospective designs, (5) restricting the study to only
postmenopausal women in the analysis, and (6) limiting the results to studies that controlled for
four or more of the important confounders.
Risk of bias was low for a majority of studies with respect to study design, cancer
assessment, and sample size; but it was high or unclear for a majority of them concerning the
handling of missing data and non-participation of subjects at each stage of follow-up. This risk
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was higher in case-control and retrospective cohort study designs compared with prospective
cohort study designs. The association between metabolic syndrome and breast cancer risk was
stronger when limited to postmenopausal women. These findings are supported by the recent
meta-analysis on metabolic syndrome and breast cancer risk in postmenopausal women.1
The current meta-analysis identified some of the methodological challenges when
pooling results from various studies examining the association between metabolic syndrome and
breast cancer risk. These include (1) the different methods used to assess exposure, identify
cancer, control for confounders, and define metabolic syndrome, (2) limiting studies to those
published in English, which may have led to inflated results, (3) the relatively small number of
studies that met the inclusion criteria, (4) the inability of a few studies to provide raw data for
calculating the risk estimates, (5) the different study designs employed, and (6) the varied
populations studied.
This study has several strengths. First, to the best of my knowledge, this is the first
systematic review and meta-analysis to examine the association between metabolic syndrome
and breast cancer risk in all adult women, with a sub-analysis of post-menopausal women.
Second, all included studies were longitudinal, reported the results of multivariable analyses, and
in eight of the nine cohorts, breast cancer was objectively determined. Third, with robust results,
tested after conducting several analyses, the findings provide direction for future.
In conclusion, the overall results of this meta-analysis suggest that there is a modest
positive association between MS and risk of breast cancer in adult females.
5.3

Study 2 Discussion: Association between individual and combined metabolic risk

factors and cancer risk
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The aim of this study was to examine whether MRFs, either individually or in
combination, were associated with the risk of overall and selected site-specific cancers of the
breast, digestive system, and lung. The overall results from this large, prospective cohort study
showed that diabetes, high BP, and the presence of a combination of three or four MRFs were
associated with higher breast cancer risk among postmenopausal women. Obesity in males less
than 50 elevated the risk of digestive cancer.
Epidemiologic evidence points toward increased risk of breast cancer in postmenopausal
diabetic women.1, 2 Diabetes is frequently associated with insulin resistance, increased
circulating concentrations of insulin, and insulin-like growth factors. Studies have shown insulin
has mitogenic effects on breast tissue.3 In addition, insulin inhibits the production of sex
hormone-binding globulin, resulting in an increase in bioavailable estradiol.4 Increased estradiol
levels have been associated with the risk of developing breast cancer.5
The finding that postmenopausal women with high BP were at an increased risk of breast
cancer is also supported by the recent meta-analysis on breast cancer risk in postmenopausal
women.1 Cancer and hypertension are both characterized by the proliferation of smooth muscle
cells.6 Another hypothesis indicates abnormalities of carcinogen binding to DNA in lymphocytes
of hypertensive women.7
Study results showing an association between a combination of three or four MRFs and a
higher risk of postmenopausal breast cancer, are supported by findings from a recent metaanalysis, suggesting that the increased risk for postmenopausal breast cancer was greater from
the combined effect of MRFs than from individual MRFs.1 A combination of MRFs may activate
different molecular pathways through metabolic, endocrine, and immune cell changes, which can
result in breast tumorigenesis.8

83

Among men, the only significant association observed was that of obesity with elevated
risk of digestive cancer. Other studies have also observed a similar association between
overweight/ obesity and digestive cancers, such as pancreatic9, 10 and colorectal11 cancers in men.
Current study has certain potential limitations. For example, blood glucose levels were
self-reported. There were no separate measures for triglycerides, or low and high-density
lipoprotein cholesterol levels (LDL and HDL). A stratified analysis could not be performed due
to small sample size for races other than white, and nonwhite had to be combined into one
category. Analyses on digestive and lung cancer could not be stratified by age because of small
number of cancer cases.
This study has several strengths. For example, data were derived using a strong
longitudinal cohort study design with high follow-up rates. In addition, self-report bias tended to
be minimized by measuring serum total cholesterol as well as blood pressure and anthropometry
(body mass index).
5.4

Study 3 Discussion: Association between metabolic risk factors and age at cancer

onset
The aim of this study was to examine whether MRFs, either individually or in
combination, were associated with age at onset of all-site cancer, and cancer of the breast,
digestive system, and lung, respectively.
Study results showed an increased risk of diabetes associated with earlier age at cancer
onset in younger and older males, and in older females. Diabetes was also associated with earlier
age at onset of postmenopausal breast cancer, and lung cancer in both genders. Presence of a
combination of three or four MRFs was associated with earlier age at onset of: (a) overall cancer
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in women 50 years and older, (b) postmenopausal breast cancer, (c) digestive cancer in females,
and (d) lung cancer in males.
Epidemiologic studies show an association between individual and combined MRFs and
elevated cancer risk. However, there are very few studies on the association of these risk factors
with age at cancer onset. Epidemiologic reviews and meta-analytic studies show people with
diabetes were at a higher risk for overall cancer and cancers of several sites, such as liver,
pancreas, endometrium, colon, rectum, breast, and bladder.5, 12 The Metabolic Syndrome and
Cancer project that comprises six large prospective cohorts found an association between
increasing levels of glucose and increased risk for incidence and mortality from cancer of lung,
trachea, and bronchus in men.13 Another cohort study found an increased risk for lung cancer
mortality in diabetic women.14
Study results show earlier age at cancer onset among older women with a combination of
three or four MRFs. This finding is supported in the literature. A meta-analysis found that
metabolic syndrome was positively associated with postmenopausal breast, endometrial,
pancreatic, and colorectal cancers in women.15 A large cohort study showed that metabolic
syndrome was associated with increased liver and breast cancer risk in women.16 Another cohort
study concluded with a significant increase in breast cancer risk among older women with two or
three MRFs, suggesting that the combined MRFs may elevate breast cancer risk beyond a single
MRF, such as obesity.17 However, studies on the association between combined MRFs and age
at cancer onset are lacking.
Studies have suggested potential biological mechanisms that link MRFs with various
cancers. In brief, through various mechanisms, including obesity, increased inflammatory
markers such as tumor necrosis factor - and interleuken-6, increased adipokines such as leptin,
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decreased adiponectin, increased levels of free fatty acids and triglycerides, insulin resistance,
increased insulin-like growth factor-1, and increased oxidative stress, MRFs have been shown to
cause angiogenesis, cell migration, mitogenesis, and DNA damage.18 There is, therefore, an
emerging hypothesis that a combination of MRFs may be an important etiologic factor for the
onset of cancer.19
This study shares similar strengths and limitations as those from the previous study.
Some of the potential limitations include self-reported diabetes diagnosis, no separate measures
for triglycerides, or low and high-density lipoprotein cholesterol levels, and small sample size for
races other than white. The study has strengths that include a longitudinal cohort study design
with high follow-up rates, and MRFs, such as total serum cholesterol as well as blood pressure
and anthropometry (body mass index) based on body measurements and laboratory data. More
importantly, there is very little research conducted on this subject.
5.5

Conclusion
The prevalence of MRFs, individually and in the aggregate, is growing rapidly.20 There is

limited biologic and epidemiologic evidence indicating an association between MRFs and
cancer. The goal of this dissertation was to examine the association between individual and
combined MRFs with subsequent risk of overall and site-specific cancers of the breast, digestive
system, and lung. Results from the meta-analysis show that the combined MRFs (metabolic
syndrome) are modestly associated with an increased risk for breast cancer in all adult women.
Results from the association between individual and combined MRFs showed that diabetes, high
BP, and the presence of a combination of three or four MRFs were associated with higher breast
cancer risk among postmenopausal women. Diabetes was also associated with earlier age at (a)
cancer onset in younger and older males, (b) cancer onset in older females, (c) postmenopausal
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breast cancer onset, and (d) lung cancer onset in both genders. Lastly, presence of a combination
of three or four MRFs was associated with earlier age at onset of: (a) overall cancer in women 50
and older, (b) postmenopausal breast cancer, (c) digestive cancer in females, and (d) lung cancer
in males.
In conclusion, study results suggest that diabetes and metabolic syndrome (or a
combination of MRFs) may serve as markers for postmenopausal breast cancer risk, but not for
overall or any other site-specific cancer risk. The association between diabetes and a
combination of three or four MRFs and earlier age at onset was observed not only for
postmenopausal breast cancer, but also for overall cancer in women 50 and older, digestive
cancer in women, and lung cancer in males.
Future research needs to determine the underlying mechanisms that may predispose
people with metabolic abnormalities to cancer. To this end, it is essential to examine the
relationship among site-specific cancers, stratified by age, gender and race, with detailed
information on triglycerides, low and high-density lipoprotein cholesterol levels, abdominal and
visceral adiposity, blood glucose levels, duration of each abnormality, and medications and their
period of use.
The positive association of a combination of MRFs with breast cancer in the metaanalysis points toward the need to develop public health strategies to manage these risk factors.
Diabetes may also serve as a marker for postmenopausal breast cancer risk. Given the
increasingly large global burden of metabolic risk factors, even a small association with breast
cancer can have a substantial public health impact. Risk assessment tools can be developed that
incorporate MRFs as a risk factor for breast cancer. Healthcare providers will then be better
equipped to identify high-risk women for primary and secondary prevention.
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Appendix A: Table 1. Criteria for Risk of Bias Assessment.
Criteria
Low Risk
Study design
Prospective or retrospective cohort,
nested case-control

High Risk

Unclear Risk
Information not
reported

Case-control

Adjustment of confounders

Adjusted for 4 or more of the
following: age, education/income,
family history of cancer, hormone
therapy use/oral contraceptive
use/reproductive history, smoking
status, and alcohol consumption

Adjusted for 3 or less of the following:
age, education/income, family history
of cancer, hormone therapy use/oral
contraceptive use/reproductive history,
smoking status, and alcohol
consumption

Information not
reported

Selection of participants and
their eligibility criteria

Studies clearly stating their eligibility
criteria and the sources and methods of
selection of participants

Studies not clearly stating their
eligibility criteria and the sources and
methods of selection of participants

Information not
reported

Measurement of predictor
variables

Identified through objective measures

Self-reported or pharmaceutical
prescriptions

Information not
reported

Breast cancer diagnosis

Histologically confirmed or identified
through cancer registry/ medical
records

Self-reported

Information not
reported

Study size

Large enough for adequate power

Not large enough for adequate power

Information not
reported

Handling of missing data

Missing data analysis specified

Missing data deleted from analysis

Information not
reported

Reasons for nonparticipation of individuals
at each stage of the study

Reasons clearly reported for each stage
of study

Reasons not reported for each stage of
study

Information not
reported
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Appendix A: Table 2. Characteristics of Studies.
Author

Year

Country

Study
Design

Sample
Size

Baseline
Year

Breast
Cancer
Cases
163

Menopausal
Status

Statistic

1987-92

Follow- Age
up
Years
2003
35-69

Agnoli et al.43

2010

Italy

Prospective
nested casecontrol

792

Post

Rate ratios

Bosco61

2011

USA

Prospective
cohort

49,172

1995

2007

21-69

1228

Mixed, post

Incidence rate
ratios

Inoue et al.62

2009

Japan

Prospective
cohort

18,176

1990-94

2004

40-69

120

Mixed, post

Hazard ratios

Kabat et al.48

2009

USA

Prospective
cohort

4,888

1993-98

2005

50-79

165

Post

Hazard ratios

Osaki et al.13

2012

Japan

Retrospectiv
e cohort

15,386

19922000

2007

20+

77

Mixed, post

Hazard ratios

Ronco et al.51

2012

Uruguay

Case-control

912

2004

2009

<70

367

Post

Odds ratios

Rosato et al. Cohort I14

2011

Italy

Case-control

3,858

1983

1994

33-86

1,988

Post

Odds ratios

Rosato et al.Cohort II14

2011

Italy and
Switzerland

Case-control

4,093

1991

2007

33-79

1,881

Post

Odds ratios

Russo et al.63

2008

Italy

Prospective
cohort

Not
reported

1999

2005

≥40

99

Mixed

Standardized
incidence
ratios

Note: Citations for the included studies are in the reference section of Chapter 2, pages 28-36.

92

Appendix A: Table 2 (continued).
Author
Exposure Assessment

Cancer Identification Confounders

Agnoli et al.43

Questionnaire,
anthropometric measures,
fasting blood draw

Cancer registry

Bosco61

Questionnaire

Medical records or
cancer registry data

Inoue et al.62

Questionnaire,
anthropometric measures,
fasting and non-fasting
blood draw
Questionnaire,
anthropometric measures,
fasting blood draw

Self-report

age, study area, smoking status, ethanol intake, physical
activity, total cholesterol

Self-report confirmed
by medical records
and tumor registry
abstracts

Questionnaire,
anthropometric measures,
fasting blood draw
Questionnaire,
anthropometric measures
after cancer

Cancer registry

age, education, ethnicity, BMI, oral contraceptive use,
postmenopausal hormone therapy, age at menarche, age at
first birth, age at menopause, alcohol, family history of breast
cancer, history of breast biopsy, physical activity, energy
intake, smoking status
age, smoking, heavy drinking

Questionnaire, waist
circumference measure

Histologically
confirmed breast
cancer

Kabat et al.48

Osaki et al.13

Ronco et al.51

Rosato et al.14

Russo et al.63

Histologically
confirmed breast
cancer

age, age at menarche, age at first birth, years from
menopause, number of full-term pregnancies, oral
contraceptives, hormone therapy, education, cancer in first
degree relatives, breastfeeding, smoking, alcohol
consumption
age, education, BMI at 18, vigorous activity

age, residence, age at menarche, parity, age at first live birth,
months of breastfeeding, use of oral contraceptives, BMI,
menopausal status, family history of BC, and intake of beef,
tomatoes and oranges
age, study center, study period, education, alcohol
consumption, age at menarche, parity and age at first birth,
age at menopause, hormone replacement therapy use, family
history of breast cancer
Not reported

Pharmaceutical
Cancer registry
prescriptions for MS
Note: Citations for the included studies are in the reference section of Chapter 2, pages 28-36.
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Appendix A: Table 3. Definitions and Criteria for Metabolic Syndrome in the Included Studies.
Agnoli et al.43

Bosco61
Inoue et al.62

Kabat et al.48

2 definitions (≥ 3 of the following components):
1. Highest or lowest (HDL-C) tertiles in controls: WC > 86 cm; Triglycerides > 126 mg/dL; HDL-C ≤= 55
mg/dL; Fasting Glucose > 88 mg/dL (or previously diagnosed T2DM); Mean BP ≥ 106.5 mmHg (or
treatment for previously diagnosed HTN).
2. NCEP: WC > 88 cm; Triglycerides ≥150 mg/dL; HDL-C < 50 mg/dL; SBP ≥130 mmHg or Diastolic BP
≥ 85 mmHg; Fasting Glucose ≥ 110 mg/dL.
≥ 3 of the following components: WC ≥ 88 cm; T2DM self-reported diagnosis at ≥ 30 years at baseline;
HTN self-reported diagnosis plus diuretics or hypertensive medication use at baseline; Cholesterol selfreported diagnosis of high cholesterol and cholesterol-lowering medication at baseline.
2 definitions:
1. Grundy (NHLBI 2005): Any 3 or more: BMI ≥ 25 kg/m2; HTN ≥130/85 mmHg or medication use;
Glucose ≥ 100 mg/dL fasting or 140 mg/dL non-fasting or on treatment; low HDL-C < 50 mg/dL;
Triglycerides ≥150 mg/dL,;
2. IDF: overweight and at least 2 other components.
ATP III modified to exclude those with Glucose ≥ 126 mg/dL or those taking diabetic medication

Osaki et al.13

6 definitions: Japan 2005, Modified NCEP 2001, Modified NCEP 2004, Modified IDF 2006, Modified
WHO 1999, NCEP 2001 with BP 140/90
51
2 definitions:
Ronco et al.
1. Diabetes+Overweight+HTN
2. Diabetes+Overweight+Dyslipidemia
14
Combined presence of diabetes, drug-treated HTN, drug-treated hyperlipidemia (as a proxy indicator of
Rosato et al.
elevated Triglycerides and reduced HDL-C), WC ≥ 88 cm or BMI ≥30 kg/m2 when WC was missing
63
Pharmacological definition - who chronically received antihypertensive, glucose-lowering, and lipid
Russo et al.
modifying drugs
Notes: BMI = Body Mass Index; BP = Blood Pressure; HDL-C = High Density Lipoprotein Cholesterol; HTN = Hypertension; WC =
Waist circumference; IDF = International Diabetes Federation; NCEP ATP III = National Cholesterol Education Program's Adult
Treatment Panel III; NHLBI = National Heart, Lung, and Blood Institute; WHO = World Health Organization.
Note: Citations for the included studies are in the reference section of Chapter 2, pages 28-36.
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Appendix A: Table 4. Study-Level Results for Risk of Bias Assessment.

Methods
Study design

Agnoli
et al.43
Low

Bosco61 Inoue
et al.62
Low
Low

Kabat
et al.48
Low

Osaki
et al.13
Low

Ronco
et al.51
High

Rosato
et al.14
High

Russo et
al.63
Low

Variables (confounders)

Low

High

High

Low

High

Low

Low

Unclear

Participants (eligibility, selection)

Low

Low

Low

Low

Low

Low

Low

Low

Data sources/ predictor measurement

Low

High

Low

Low

Low

High

High

High

Data sources/ outcome measurement

Low

Low

High

Low

Low

Low

Low

Low

Study size (adequate power)

Low

Low

Low

Low

Low

Low

Low

Low

Missing data analysis

High

High

High

Low

High

Low

Unclear

Unclear

High

High

High

High

Low

Low

High

High

Results
Participants (non-participation)

Note: Citations for the included studies are in the reference section of Chapter 2, pages 28-36.
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Initial records identified = 401
Web of Science (n = 295)
PubMed (n = 79)
CINAHL* (n = 15)
ProQuest (n = 12)
Cross-referencing (n = 0)

Records after duplicates
removed (n = 291)

Initial records screened based
on title and abstracts (n = 291)

Full-text articles assessed for
eligibility (n = 47)

Articles included in metaanalysis (n = 8), 9 independent
cohorts

Reason for excluding records on first screening: Predictor and/or
outcome not reported (n = 244)

Reasons for excluding records after full-text review (n=39)
• Individual metabolic syndrome components (not combined
syndrome) (n = 13)
• Not original epidemiological study (n = 7)
• Review articles (n = 7)
• Breast cancer patients only (n = 5)
• Cross-sectional study (n = 4)
• MS measured as added individual z-scores (n = 1)
• Not breast cancer (n = 2)

Figure 1. Flow diagram describing the selection of studies.
*CINAHL: Cumulated Index to Nursing and Allied Health Literature.
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Study name

Statistics for each study
Risk
ratio

Lower
limit

Upper
limit

Agnoli, 2010

1.58

1.07

2.33

Bosco, 2011

1.14

0.79

1.64

Inoue, 2009

0.82

0.50

1.35

Kabat, 2009

1.12

0.78

1.61

Osaki, 2012

2.87

1.67

4.94

Ronco, 2012

5.79

1.52

22.03

Rosato-I, 2011

1.76

1.03

3.01

Rosato-II, 2011

1.87

1.42

2.47

Russo, 2008

1.17

0.95

1.44

1.47

1.15

1.87

Risk ratio and 95% CI

0.1 0.2

0.5

Reduced Risk

1

2

5

10

Increased Risk

Figure 2. Forest plot for metabolic syndrome and breast cancer risk (random-effects model).
The black circles represent the weighted risk ratio (RR) for each result from each study while the horizontal lines represent the lower and
upper 95% confidence intervals (CI) for the RR. The black diamond represents the overall pooled RR while the left and right sides of the
diamond represent the lower and upper 95% CI for the pooled RR. For studies that included more than one definition of metabolic syndrome,
the following were used: Agnoli et al. (tertile definition), Bosco (time-independent definition), Osaki et al. (modified NCEP 2001 definition),
Ronco et al. (diabetes, overweight and hypertension definition).
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Funnel Plot of Precision by Log risk ratio
10

Precision (1/Std Err)

8

6

4

2

0
-2.0

-1.5

-1.0

-0.5

0.0

0.5

1.0

1.5

2.0

Log risk ratio

Figure 3. Funnel plot and Trim and Fill procedure for assessing publication bias.
The white circles represent the log risk ratios (LRR) for each result from each study while the black circles represent the imputed LRR (n =
2). The white diamond represents the pooled LRR while the black diamond represents the pooled LRR, including the two imputed values.
The left and right sides of each diamond represent the lower and upper 95% confidence intervals. For those studies that included more than
one definition of metabolic syndrome, the following were used: Agnoli et al. (tertile definition), Bosco (time independent definition), Osaki
et al. (modified NCEP 2001 definition), and Ronco et al. (diabetes, overweight and hypertension definition).
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Study name

Statistics with study removed
Point

Lower
limit

Risk ratio (95% CI) with study removed

Upper
limit

Osaki, 2012

1.36

1.09

1.70

Rosato-II, 2011

1.41

1.09

1.82

Ronco, 2012

1.41

1.12

1.77

Rosato-I, 2011

1.44

1.11

1.88

Agnoli, 2010

1.46

1.11

1.92

Bosco, 2011

1.53

1.17

2.01

Kabat, 2009

1.54

1.17

2.01

Russo, 2008

1.54

1.16

2.05

Inoue, 2009

1.56

1.22

1.99

1.47

1.15

1.87
0.1

0.2

0.5

Reduced Risk

1

2

5

10

Increased Risk

Figure 4. Influence analysis with each result from each study deleted from the random-effects model once.
The black circles represent the risk ratio (RR) for each result from each study while the horizontal lines represent the lower and upper 95%
confidence interval (CI) for the RR. The black diamond represents the overall pooled result while the left and right sides of the diamond
represent the lower and upper 95% CI for the pooled RR. For studies that included more than one definition of metabolic syndrome, the
following were used: Agnoli et al. (tertile definition), Bosco (time-independent definition), Osaki et al. (modified NCEP 2001 definition),
and Ronco et al. (diabetes, overweight and hypertension definition).
99

Study name

Cumulative statistics

Point

Lower
limit

Cumulative risk ratio (95% CI)

Upper
limit

Russo, 2008

1.17

0.95

1.44

Inoue, 2009

1.06

0.77

1.45

Kabat, 2009

1.11

0.94

1.32

Agnoli, 2010

1.17

0.96

1.44

Bosco, 2011

1.17

1.01

1.36

Rosato-I, 2011

1.21

1.03

1.43

Rosato-II, 2011

1.31

1.07

1.61

Osaki, 2012

1.41

1.12

1.77

Ronco, 2012

1.47

1.15

1.87

1.47

1.15

1.87

0.5

1

Reduced Risk

2

Increased Risk

Figure 5. Cumulative meta-analysis, ranked by year and based on a random-effects model.
The black circles represent the cumulative risk ratios (RR) for each result from each study while the horizontal lines represent the lower and
upper 95% confidence intervals for the RR. The black diamond represents the overall pooled RR while the left and right sides of the diamond
represent the lower and upper 95% confidence intervals for the pooled RR. For those studies that included more than one definition of
metabolic syndrome, the following were used: Agnoli et al. (tertile definition), Bosco (time independent definition), Osaki et al. (modified
NCEP 2001 definition), and Ronco et al. (diabetes, overweight and hypertension definition).
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Appendix B: Association between metabolic risk factors and cancer risk
Table 1: Characteristics of the Study Population, National Health and Nutrition
Examination Survey I (NHANES I) Epidemiologic Follow-up Study, 1971-1992
(Unweighted sample size = 10,694 )
Characteristics of the study
population
Age at baseline (years)
Women
Men
Race/ethnicity
White
Non-white
Family income
Below $5,000
$5,001 - $15,000
Above $15,000
Education
High school or less
Above high school
Physical activity
Moderately or very active
Quite inactive
Smoked 100 cigarettes in lifetime
Yes
No
Missing
Family history of cancer
Yes
No
Missing
BMI, kg/m2
BMI categories
Underweight
Healthy weight
Overweight
Obese
Blood pressure
High BP
No high BP
Diastolic (mmHg)
Systolic (mmHg)

Total

%

6339
4355

59.3
40.7

9125
1569

85.3
14.7

2794
5558
2342

26.1
52.0
21.9

8159
2535

76.3
23.7

9652
1042

90.3
9.7

5786
4477
431

54.1
41.9
4.0

3763
6006
925

35.2
56.2
8.6

Mean (SE)
48.78 (0.15)

25.68 (0.05)
333
5020
3562
1779

3.1
46.9
33.3
16.6

4851
5843

45.4
54.6
83.54 (0.13)
134.03 (0.23)
Continued...
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Serum cholesterol (mg/dL)
High (>=240 mg/dL)
Not high cholesterol
Diabetes
Yes
No
Missing
Metabolic Risk Factor (MRF)
MRF 0
MRF 1
MRF 2
MRF 3 or 4
Missing

220.82 (0.47)
3383
7311

31.6
68.4

518
7969
2207

4.8
74.5
20.6

3031
2925
1924
607
2322

28.3
27.4
18.0
5.7
21.7

Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; MRF, Metabolic Risk Factor;
SE, Standard Error.
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Appendix B
Table 2: Association between Individual Metabolic Risk Factors and Cancer Risk among Males
Age <50 Years (n = 1972, Cancer cases = 140)
Variable

Cancer cases

Sample size

BMI≥30

18

244

BMI<30

122

1728

High BP

56

741

< High BP

84

1231

Cholesterol≥240

44

484

Cholesterol<240

96

1488

4

37

102

1350

34

585

Diabetes
No Diabetes
Missing

Hazard ratioa
(95% CI)
1.00 (0.57, 1.76)
Referent
0.89 (0.63, 1.25)
Referent
1.21 (0.85, 1.72)
Referent
1.02 (0.32, 3.29)
Referent

Age ≥ 50 Years (n = 2383, Cancer cases = 691)
Cancer cases

Sample size

89

323

602

2060

398

1498

293

885

232

855

459

1528

34

175

524

1794

133

414

Hazard ratioa
(95% CI)
1.08 (0.81, 1.46)
Referent
0.84 (0.68, 1.05)
Referent
1.00 (0.81, 1.23)
Referent
1.05 (0.60, 1.84)
Referent

Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.
a
Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 3: Association between Individual Metabolic Risk Factors and Cancer Risk among Females
Age <50 Years (n = 3722, Cancer cases = 364)
Variable

Cancer cases

Sample size

BMI≥30

70

575

BMI<30

294

3147

High BP

96

843

< High BP

268

2879

Cholesterol≥240

83

617

Cholesterol<240

281

3105

10

72

293

2898

61

752

Diabetes
No Diabetes
Missing

Hazard ratioa
(95% CI)
1.18 (0.80, 1.74)
Referent
1.02 (0.71, 1.46)
Referent
1.20 (0.89, 1.61)
Referent
0.91 (0.38, 2.17)
Referent

Age ≥ 50 Years (n = 2617, Cancer cases = 572)
Cancer cases

Sample size

129

637

443

1980

375

1769

197

848

322

1427

250

1190

39

234

441

1927

92

456

Hazard ratioa
(95% CI)
0.74 (0.54, 0.99)
Referent
0.97 (0.78, 1.21)
Referent
1.27 (1.01, 1.58)
Referent
1.12 (0.70, 1.78)
Referent

Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.
a
Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 4: Association between Combined Metabolic Risk Factors Score and Cancer Risk among Males
Age <50 Years (n = 1987, Cancer cases = 141)
Variable

Cancer cases

Sample size

5

53

MRF 2

21

MRF 1

Hazard ratioa
(95% CI)

Age ≥ 50 Years (n =2396, Cancer cases = 692)
Hazard ratioa
(95% CI)

Cancer cases

Sample size

1.09 (0.40, 2.98)

23

120

0.63 (0.35, 1.12)

205

1.11 (0.68, 1.80)

148

591

0.81 (0.59, 1.12)

37

501

0.92 (0.55, 1.55)

250

850

0.93 (0.67, 1.28)

MRF 0

43

628

137

408

Missing

35

600

134

427

MRF 3 or 4

Referent

Referent

Abbreviations: CI, Confidence Interval; MRF, Metabolic Risk Factor.
a
Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 5: Association between Combined Metabolic Risk Factors Score and Cancer Risk among Females
Age <50 Years (n = 3773, Cancer cases = 371)
Variable

Sample size

Cancer cases

MRF 3 or 4

13

70

MRF 2

50

MRF 1

Hazard ratioa
(95% CI)

Age ≥ 50 Years (n = 2653, Cancer cases = 580)
Hazard ratioa
(95% CI)

Sample size

Cancer cases

1.30 (0.65, 2.60)

75

364

1.14 (0.69, 1.90)

351

1.41 (0.90, 2.20)

175

777

0.99 (0.68, 1.44)

81

816

1.04 (0.75, 1.43)

165

758

0.92 (0.64, 1.32)

MRF 0

159

1733

65

262

Missing

68

803

100

492

Referent

Referent

Abbreviations: CI, Confidence Interval; MRF, Metabolic Risk Factor.
a
Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 6: Association between Individual Metabolic Risk Factors and Breast Cancer Risk among Females
All women (n = 6339, Cancer cases = 236)
Variable

Cancer cases

Sample size

BMI≥30

50

1212

BMI<30

186

5127

High BP

107
129

2612

Cholesterol≥240

89

2044

Cholesterol<240

147

4295

14

306

177

4825

45

1208

< High BP

Diabetes
No Diabetes
Missing

3727

Hazard ratioa
(95% CI)
0.81 (0.51, 1.31)
Referent
1.19 (0.81, 1.73)
Referent
1.13 (0.78, 1.63)
Referent
1.63 (0.81, 3.29)
Referent

Postmenopausal women
(n =2954, Cancer cases =124)
Hazard ratioa
(95% CI)

Cancer cases

Sample size

33

700

91

2254

Referent

83

1847

1.70 (1.001, 2.88)

41

1107

Referent

66

1487

58

1467

13

245

83

2171

28

538

0.80 (0.43, 1.50)

1.16 (0.75, 1.79)
Referent
2.32 (1.09, 4.95)
Referent

Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.
a
Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 7: Association between Combined Metabolic Risk Factors Score and Breast Cancer Risk among Females
All women
(n = 6426, Cancer cases = 239)
Variable

Cancer cases

Sample size

MRF 3 or 4

21

434

MRF 2

46

MRF 1

Hazard ratioa
(95% CI)

Postmenopausal women
(n = 2998, Cancer cases = 126)
Hazard ratioa
(95% CI)

Cancer cases

Sample size

1.44 (0.68, 3.04)

19

365

3.26 (1.23, 8.65)

1128

1.09 (0.62, 1.92)

34

819

2.16 (0.89, 5.22)

56

1574

0.93 (0.57, 1.52)

30

837

1.53 (0.64, 3.62)

MRF 0

68

1995

13

395

Missing

48

1295

30

582

Referent

Referent

Abbreviations: CI, Confidence Interval; MRF, Metabolic Risk Factor.
a
Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).

109

Appendix B
Table 8: Association between Individual Metabolic Risk Factors and Digestive Cancer Risk by Gender
Males (n = 4355, Cancer cases = 196)
Variable

Cancer cases

Sample size

BMI≥30

36

567

BMI<30

160

3788

High BP

116

2239

< High BP

80

2116

Cholesterol≥240

57

1339

Cholesterol<240

139

3016

9

212

148

3144

39

999

Diabetes
No Diabetes
Missing

Hazard ratioa
(95% CI)
1.92 (1.15, 3.21)
Referent
1.02 (0.65, 1.59)
Referent
0.90 (0.58, 1.38)
Referent
1.47 (0.54, 4.01)
Referent

Females (n = 6339, Cancer cases = 207)
Cancer cases

Sample size

52

1212

155

5127

132

2612

75

3727

107

2044

100

4295

13

306

168

4825

26

1208

Hazard ratioa
(95% CI)
0.86 (0.58, 1.29)
Referent
1.36 (0.93, 1.99)
Referent
1.32 (0.93, 1.87)
Referent
0.89 (0.36, 2.17)
Referent

Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.
a
Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 9: Association between Combined Metabolic Risk Factors and Digestive Cancer Risk by Gender
Males (n = 4383, Cancer cases = 196)
Variable

Cancer cases

Sample size

7

173

MRF 2

43

MRF 1

Females (n = 6426, Cancer cases = 211)

Hazard ratioa
(95% CI)

Hazard ratioa
(95% CI)

Cancer cases

Sample size

1.32 (0.42, 4.16)

28

434

1.05 (0.54, 2.05)

796

1.32 (0.66, 2.65)

67

1128

0.98 (0.58, 1.65)

69

1351

1.35 (0.71, 2.56)

44

1574

0.49 (0.26, 0.91)

MRF 0

38

1036

42

1995

Missing

39

1027

30

1295

MRF 3 or 4

Referent

Referent

Abbreviations: CI, Confidence Interval; MRF, Metabolic Risk Factor.
a
Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 10: Association between Individual Metabolic Risk Factors and Lung Cancer Risk by Gender
Males (n = 4355, Cancer cases = 174)
Variable

Cancer cases

Sample size

BMI≥30

20

567

BMI<30

154

3788

High BP

86

2239

< High BP

88

2116

Cholesterol≥240

56

1339

Cholesterol<240

118

3016

9

212

131

3144

34

999

Diabetes
No Diabetes
Missing

Hazard ratioa
(95% CI)
0.97 (0.48, 1.95)
Referent
0.86 (0.60, 1.24)
Referent
1.22 (0.85, 1.75)
Referent
1.14 (0.45, 2.87)
Referent

Females (n = 6339, Cancer cases = 81)
Cancer cases

Sample size

15

1212

66

5127

39

2612

42

3727

38

2044

43

4295

6

306

58

4825

17

1208

Hazard ratioa
(95% CI)
0.85 (0.38, 1.91)
Referent
0.62 (0.33, 1.14)
Referent
1.51 (0.80, 2.84)
Referent
1.70 (0.52, 5.56)
Referent

Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.
a
Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 11: Association between Combined Metabolic Risk Factors and Lung Cancer Risk by Gender
Males (n = 4383, Cancer cases = 175)
Variable
MRF 3 or 4

Cancer cases

Sample size

Females (n = 6426, Cancer cases = 83)
Hazard ratioa
(95% CI)

Cancer cases

Sample size

Hazard ratioa
(95% CI)

5

173

1.05 (0.25, 4.46)

6

434

0.66 (0.14, 3.09)

MRF 2

30

796

0.93 (0.51, 1.68)

20

1128

0.76 (0.31, 1.84)

MRF 1

65

1351

1.22 (0.66, 2.26)

20

1574

0.63 (0.26, 1.57)

MRF 0

40

1036

18

1995

Missing

35

1027

19

1295

Referent

Referent

Abbreviations: CI, Confidence Interval; MRF, Metabolic Risk Factor.
a
Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Appendix C: Association between metabolic risk factors and age at cancer onset
Table 1. Characteristics of the Study Population, National Health and Nutrition
Examination Survey I (NHANES I) Epidemiologic Follow-up Study, 1971-1992
(Unweighted sample size = 1,736 )
Characteristics of the study population
Age at baseline (years)
Age at cancer (years)
Women
Men
Race/ethnicity
White
Non-white
Family income
Below $5,000
$5,001 - $15,000
Above $15,000
Education
High school or less
Above high school
Physical activity
Moderately or very active
Quite inactive
Smoked 100 cigarettes in lifetime
Yes
No
Missing
Family history of cancer
Yes
No
Missing
BMI, kg/m2
BMI categories
Underweight
Healthy weight
Overweight
Obese
Blood pressure (mmHg)
Diastolic
Systolic
High BP
No high BP

Frequency

%

Mean (SE)
56.4 (0.31)
67.9 (0.31)

914
822

52.6
47.4

1502
234

86.5
13.5

543
864
329

31.3
49.8
19.0

1400
336

80.6
19.4

1559
177

89.8
10.2

984
673
79

56.7
38.8
4.6

707
845
184

40.7
48.7
10.6
26.0 (0.12)

31
765
641
299

1.8
44.1
36.9
17.2
84.3 (0.31)
137.7 (0.57)

902
834

52.0
48.0
Continued...
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Serum cholesterol (mg/dL)
High (>=240 mg/dL)
Low (< 240 mg/dL)
Diabetes
Yes
No
Missing
Metabolic Risk Factor (MRF)
MRF 0
MRF 1
MRF 2
MRF 3 or 4
Missing

228.7 (1.23)
668
1068

38.5
61.5

84
1334
318

4.8
76.8
18.3

400
522
383
113
335

23.0
30.1
22.1
6.5
19.3

Abbreviations: BMI, Body mass index; SE, Standard error.
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Table 2: Association between Individual Metabolic Risk Factors and Age at Cancer Onset among Males
Age <50 Years (n= 140)
Variable

Cancer cases

BMI≥30 kg/m2

18

2

122

BMI<30 kg/m
High BP

56

< High BP

84

Cholesterol≥240 mg/dL

44

Cholesterol<240 mg/dL

96

Diabetes
No Diabetes
Missing

4
102
34

Mean differencea
(95% CI)
2.71 (0.96, 4.47)
Referent
1.47 (-0.25, 3.20)
Referent
-1.47 (-3.45, 0.51)
Referent
-4.36 (-7.77, -0.96)
Referent

Age ≥ 50 Years (n = 682)
Cancer cases
87
595
391
291
230

Mean differencea
(95% CI)
0.27 (-0.99, 1.53)
Referent
0.04 (-0.96, 1.05)
Referent
0.45 (-0.39, 1.30)

452

Referent

33

-2.78 (-5.34, -0.22)

517

Referent

132

Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000,
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 3: Association between Individual Metabolic Risk Factors and Age at Cancer Onset among Females
Age <50 Years (n = 362)

Age ≥ 50 Years (n = 552)

Cancer cases

Mean differencea
(95% CI)

Cancer cases

BMI≥30 kg/m2

69

-0.80 (-2.39, 0.79)

125

2

293

Referent

427

High BP

96

1.25 (-0.10, 2.61)

359

< High BP

266

Referent

193

Cholesterol≥240 mg/dL

83

0.32 (-0.77, 1.41)

311

Cholesterol<240 mg/dL

279

Referent

241

Referent

-0.20 (-3.47, 3.08)

38

-1.97 (-3.72, -0.21)

Referent

423

Referent

Variable

BMI<30 kg/m

Diabetes
No Diabetes
Missing

9
292
61

Mean differencea
(95% CI)
-0.89 (-2.29, 0.51)
Referent
-0.05 (-1.13, 1.02)
Referent
-0.20 (-1.12, 0.72)

91

Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000,
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 4: Association between Combined Metabolic Risk Factors and Age at Cancer Onset among Males
Age <50 Years (n = 141)

Age ≥ 50 Years (n = 683)

Cancer cases

Mean differencea
(95% CI)

Cancer cases

5

2.65 (-0.79, 6.10)

22

0.73 (-2.36, 3.82)

MRF 2

21

0.90 (-2.50, 4.30)

146

0.13 (-1.35, 1.61)

MRF 1

37

-0.18 (-2.30, 1.95)

247

-0.40 (-1.71, 0.92)

MRF 0

43

Referent

135

Referent

Missing

35

Variable
MRF 3 or 4

Mean differencea
(95% CI)

133

Abbreviations: CI, Confidence Interval, MRF, Metabolic Risk Factor.
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000,
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 5: Association between Combined Metabolic Risk Factors and Age at Cancer Onset among Females
Age <50 Years (n = 369)

Age ≥ 50 Years (n = 560)

Cancer cases

Mean differencea
(95% CI)

Cancer cases

MRF 3 or 4

13

2.78 (0.41, 5.14)

73

-2.64 (-4.60, -0.68)

MRF 2

50

0.48 (-1.08, 2.05)

166

0.29 (-1.62, 2.20)

MRF 1

79

-0.77 (-2.38, 0.85)

159

-0.25 (-2.05, 1.55)

MRF 0

159

Referent

63

Missing

68

Variable

Mean differencea
(95% CI)

Referent

99

Abbreviations: CI, Confidence Interval, MRF, Metabolic Risk Factor.
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000,
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 6: Association between Individual Metabolic Risk Factors and Age at Breast Cancer Onset among Females
All women (n = 223)
Variable

Cancer cases

BMI≥30 kg/m2
BMI<30 kg/m

2

48
181

High BP

101

< High BP

128

Cholesterol≥240 mg/dL

88

Cholesterol<240 mg/dL

141

Diabetes

14
169

No Diabetes
Missing

46

Mean differencea
(95% CI)
-1.78 (-3.78, 0.23)
Referent
1.02 (-0.96, 3.00)
Referent
-0.60 (-2.53, 1.33)
Referent
-2.78 (-5.82, 0.25)
Referent

Postmenopausal women (n = 112)
Cancer cases

Mean differencea
(95% CI)

31

-0.37 (-2.64, 1.90)

81

Referent

75

0.10 (-2.30, 2.50)

37

Referent

60

-0.93 (-3.30, 1.43)

52

Referent

13

-2.61 (-4.89, -0.33)

72

Referent

27

Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000,
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 7: Association between Combined Metabolic Risk Factors and Age at Breast Cancer Onset among Females
All women (n = 226)
Variable

Cancer cases

Mean differencea
(95% CI)

Postmenopausal women (n = 114)
Cancer cases

Mean differencea
(95% CI)

MRF 3 or 4

21

-3.31 (-6.12, -0.50)

19

-3.84 (-6.71, -0.96)

MRF 2

44

-0.98 (-4.08, 2.13)

29

-2.55 (-6.31, 1.20)

MRF 1

51

-2.13 (-4.27, 0.01)

26

-2.46 (-5.41, 0.48)

MRF 0

67

Missing

50

Referent

11

Referent

29

Abbreviations: CI, Confidence Interval, MRF, Metabolic Risk Factor.
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000,
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 8: Association between Individual Metabolic Risk Factors and Age at Digestive Cancer Onset by Gender
Males (n = 194)

Females (n = 203)

Cancer cases

Mean differencea
(95% CI)

Cancer cases

BMI≥30 kg/m2

34

0.17 (-2.01, 2.36)

51

-1.66 (-3.45, 0.13)

2

160

Referent

152

Referent

High BP

114

0.79 (-1.08, 2.66)

128

-1.03 (-2.80, 0.75)

< High BP

80

Referent

75

Referent

Cholesterol≥240 mg/dL

57

0.34 (-1.53, 2.22)

104

Cholesterol<240 mg/dL

137

Referent

99

Referent

-0.21 (-3.04, 2.62)

13

-2.21 (-4.88, 0.46)

Referent

164

Referent

Variable

BMI<30 kg/m

Diabetes
No Diabetes
Missing

9
147
38

Mean differencea
(95% CI)

0.17 (-1.75, 2.08)

26

Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000,
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 9: Association between Combined Metabolic Risk Factors and Age at Digestive Cancer Onset by Gender
Males (n = 194)

Females (n = 207)

Cancer cases

Mean differencea
(95% CI)

Cancer cases

7

0.98 (-2.26, 4.22)

27

-4.42 (-6.63, -2.22)

MRF 2

42

1.04 (-1.73, 3.82)

65

-1.35 (-3.64, 0.95)

MRF 1

69

-0.67 (-2.83, 1.50)

43

-3.09 (-5.41, -0.77)

MRF 0

38

Referent

42

Referent

Missing

38

Variable
MRF 3 or 4

Mean differencea
(95% CI)

30

Abbreviations: CI, Confidence Interval, MRF, Metabolic Risk Factor.
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000,
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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Table 10: Association between Individual Metabolic Risk Factors and Age at Lung Cancer Onset by Gender
Males (n = 174)
Variable

Cancer cases

BMI≥30 kg/m2

20

2

154

BMI<30 kg/m
High BP

86

< High BP

88

Cholesterol≥240 mg/dL

56

Cholesterol<240 mg/dL

118

Diabetes
No Diabetes
Missing

9
131
34

Mean differencea
(95% CI)
-0.44 (-2.78, 1.91)
Referent
0.66 (-1.02, 2.34)
Referent
0.29 (-1.60, 2.17)

Females (n = 80)
Cancer cases
15
65
38
42
37

Mean differencea
(95% CI)
1.34 (-0.73, 3.40)
Referent
1.07 (-0.90, 3.04)
Referent
0.46 (-1.71, 2.62)

Referent

43

Referent

-7.40 (-10.37, -4.43)

6

-4.59 (-8.18, -1.01)

Referent

57

Referent

17

Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000,
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).

125

Appendix C
Table 11: Association between Combined Metabolic Risk Factors and Age at Lung Cancer Onset by Gender
Males (n = 175)
Variable
MRF 3 or 4

Cancer cases

Mean differencea
(95% CI)

Females (n = 82)
Cancer cases

Mean differencea
(95% CI)

5

-3.76 (-6.63, -0.88)

6

-2.92 (-8.93, 3.10)

MRF 2

30

0.44 (-2.44, 3.32)

19

-0.05 (-3.53, 3.44)

MRF 1

65

-1.36 (-3.53, 0.82)

20

-0.87 (-4.00, 2.25)

MRF 0

40

18

Referent

Missing

35

Referent

19

Abbreviations: CI, Confidence Interval, MRF, Metabolic Risk Factor.
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000,
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive).
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